

- Abyssinine A, 100, 112, 114–115, 128–129
 Abyssinine B, 100, 114–115, 126, 127
 Abyssinine C, 100, 115
 14-Acetylaconosine, *see* Dolaconine
 6-O-Acetylacosepticine, 40, 58–59
 6-O-Acetylacosepticine, 17–18, 29, 31
 14-Acetyldihydrogadesine, 31
 8-Acetyldolaconine, 7, 31, 34, 46
 plant sources of, 7, 27
 8-Acetylexcelsine, 15, 31, 38
 plant sources of, 15, 28
 N-Acetylhystrine, 151–153
 Acetyl-nornicotine, 154
 N-Acetylsepaconitine, 14–15, 31, 38, 53–54
 pharmacological activity of, 71
 plant sources of, 14–15, 28
 6-O-Acetylbubofrine, 17–18, 31, 40, 57
 plant sources of, 17–18, 29
 Aconitine, 191, 196
 lappaconitine v., 3
Aconitum spp.
 diterpene alkaloids in, 191–193
 C₁₈-diterpenoid alkaloids from, 5, 27–30
 Aconosine
 classification and structure of, 2, 6, 31, 34, 46
 plant sources of, 6, 27–29
 Aconosine-subtype, classification and structure of, 3–9, 34–35, 46–49
 Acosepticine, 17, 31, 40, 57
 plant sources of, 17, 29
 Acoseptrine, 18, 31, 40, 58–59
 plant sources of, 18, 29
 Activity, *see* Structure–activity relationships and mechanisms of action
 Adouetine X, 87, 112, 117–119
 Adouetine Y, 92, 116, 118, 131–132
 Adouetine Y', 87, 112, 116–119, 125, 133
 Adouetine Z, 94, 118–119
 5(14)-Adouetine Z type cyclopeptide alkaloids, 94
 Ajmalicine, 250–251
 Akiradin, 15, 31, 38
 plant sources of, 15, 28
 Akiramidine, 10, 31, 36
 plant sources of, 10, 28
 Akiramine, 11, 31, 36, 50–51
 plant sources of, 11, 28
 Akiran, 11, 31, 36
 plant sources of, 11, 28
 Akiranine, 10, 31, 36, 50–51
 plant sources of, 10, 28
 Akirine, 16, 31, 38
 plant sources of, 16, 28
 Albine, 246
 Alkaloid 2, 82, 112, 118
 Alkaloid 3, 84, 112
 Alkaloid 4, 87, 118
 Alkaloid 6, 92
 Alkaloid glycoprocessing inhibitors, 166–168
 AM-1, 87, 119
 AM-2, 92, 119
 Americine, 87, 117, 131–132
 Ammodendrine, 151–153, 169–170, 175
 Amphibine A, 87, 113–115
 Amphibine B, 97, 114
 5(14)-Amphibine B type cyclopeptide alkaloids, 97–98, 108–109
 Amphibine C, 97, 114
 Amphibine D, 97, 113–115
 Amphibine E, 97, 114–115
 Amphibine F, 95, 114–115
 4(14)-Amphibine F type cyclopeptide alkaloids, 95–96, 107–108
 Amphibine G, 95, 114
 Amphibine H, 84, 113–115
 Anabaseine, 154–155, 157
 (–)-Anabasine, 154–157
 Anacrotine, 184
 Anagryne, 169–175
 Analgesic activity, of C₁₈-diterpenoid alkaloids, 39, 69
 S-(–)-Anatabine, 154–156
 Ancistrocladaceae family, antimalarial alkaloids of, 238
 Ancistrocladidine, 238
 Ancistrocladine, 238
 Ancistrocladinidine, 238
 Ancistrocladisine, 238

- Ancistroheynine A, 238–239
- Anesthetic activity, of C_{18} -diterpenoid alkaloids, 72
- Angel's trumpet, toxic alkaloids of, 176
- 7-Angelyl heliotridine (Rivularine), 180–181, 183
- 7-Angelyl heliotrine, 180–181
- Angustifoline, 246–247
- Anisodamine, 242
- Anorldianine, 87, 119
- Anorldianine 27-N-oxide, 103, 110, 119
- 4-Anthranoyllappaconitine
classification and structure of, 11–12, 31, 37, 52–53
plant sources of, 11–12, 29
- Anthriscifolcine A, 19, 31, 41, 58–59
plant sources of, 19, 29
- Anthriscifolcine B, 18, 31, 40, 58–59
plant sources of, 18, 29
- Anthriscifolcine C, 19, 31, 41, 59–60
plant sources of, 19, 29
- Anthriscifolcine D, 19–20, 31, 41–42, 59–60
plant sources of, 19–20, 29
- Anthriscifolcine E, 19–20, 31, 41, 59–60
plant sources of, 19–20, 29
- Anthriscifolcine F, 19–20, 31, 42, 59–60
plant sources of, 19–20, 30
- Anthriscifolcine G, 19, 31, 41, 58–59
plant sources of, 19, 30
- Antiarrhythmic activity, of
 C_{18} -diterpenoid alkaloids, 69–72
- Anticholinergic activity, of hyoscyamine and scopolamine, 178–179
- Antidesma* spp., cyclopeptide alkaloids from, 119
- Anti-inflammatory activity, of
 C_{18} -diterpenoid alkaloids, 72
- Antimalarial isoquinoline and naphthylisoquinoline alkaloids, IR and Raman spectroscopy of, 234–239
- Antimicrobial activity, of cyclopeptide alkaloids, 133
- Antispasmodial activity, of cyclopeptide alkaloids, 133
- Arabica coffee beans, quantification of caffeine in, 225
- Aralionine A, 92, 118
- Aralionine B, 92, 118, 119
- Aralionine C, 92, 118
- Araliorhammus* spp., cyclopeptide alkaloids from, 118
- Argemone oil, 190
- Argemone* spp., toxic alkaloids of, 188–190
- Astragalus* spp., toxic alkaloids in, 158–160, 163–164
- Atropine, 177
- Australine, 160–161, 166–167
- 1-*epi*-Australine, 160–161, 166–167
- 1-*epi*-Australine 2-O- β -D-glucopyranoside, 160–161, 166–167
- Baptisia* spp., toxic alkaloids of, 171
- Barbinine, 194
- Benzoylmethyl ecgonine, *see* Cocaine
- Benzylisoquinoline alkaloids, IR and Raman spectroscopy of, 239–241
- Berberine, 188
IR and Raman spectroscopy of, 233–234
- Biological activity, *see* Pharmacological activity
- Biosynthesis, of cyclopeptide alkaloids, 130–132
- Bipiperidine alkaloids, 151–154
- Bisnorditerpenoid alkaloids, *see* C_{18} -Diterpenoid alkaloids
- Black Bean, toxic alkaloids of, 160–161, 164–169
- Bluebell, *see* English bluebell
- Bohlmann bands, 219–220
- Brugmansia* spp., toxic alkaloids of, 176
- 6-O-Butanoylcastanospermine (Celgosivir), 168
- Caffeine, 220–227
- Calystegia sepium*, toxic alkaloids of, 162
- Calystegines, 159, 162–163, 165–167, 178
- Camas, toxic alkaloids of, 203–205
- Candarine A, 117
- Canthium* spp., cyclopeptide alkaloids from, 119
- Canthiumine, 92, 119
- Capsaicin, 251–252
- Cardiodine, 249–250
- Cardionidine, 249–250
- Cardiopidine, 249–250
- Cardiopimine, 249–250
- Cardiopine, 249–250
- Cardiopinine, 249–250
- Castanospermine, 160–161, 165–169

- 6-*epi*-Castanospermine, 160
Castanospermum australe, toxic alkaloids of, 160–161, 164–169
Ceanothine A, 87, 117
Ceanothine B, 88, 117
Ceanothine C, 88, 117
Ceanothine D, 103, 117
Ceanothine E, 92, 117, 131–132
Ceanothus spp., cyclopeptide alkaloids from, 117
Celandine, medicinal alkaloids of, 239
Celgosivir, *see* 6-O-Butanoylcastanospermine
Cevanines, 202
Cevanine-type steroidal alkaloids, 203–205
Chamaedrine, 88, 106, 119, 122
Chelerythrine, 239–240
Chemometrics
 of caffeine, 225, 227
 of capsaicin, 252
 of cocaine, 242
 of heroin, 232–233
 of nicotine, 243
 for piperine, 245
 of quinine and quinidine, 237
 of theobromine, 227
Chlorogenic acid, 225–226
Cholestanes, 201–202
Cinchona spp., alkaloids of, 235–236
Cinchonidine, 235
Cinchonine, 235
Clinical signs of poisoning, *see* Toxicity
Cocaine, 233, 241–242
Codeine, 229–231, 233
Coffee, quantification of caffeine in, 225–226
Colubrina spp., cyclopeptide alkaloids from, 117
Condalia spp., cyclopeptide alkaloids from, 117
Condaline A, 92, 107, 124, 125–126, 133
Conhydrine, 147–148
Conhydrinone, 147–148
 γ -Coniceine, 147–148, 150–151
(R)-(-)-Coniine, 147–148, 150
Conium maculatum, toxic alkaloids of, 147–151
Consolida spp., C₁₈-diterpenoid alkaloids from, 5, 30
Contortumine, 8, 31, 35, 48–49
 plant sources of, 8, 27
Corynantheine, 250–251
Cossonidine, 249–250
Crenatine A, 92, 116
Crooked calf disease, 173
Crotalaria spp., toxic alkaloids of, 183–186
Cycloamine, 199–202
Cyclopeptide alkaloids, from higher plants, 79–135
 biological activity of, 131–135
 antimicrobial, 133
 antispasmodial, 133
 sedative, 134
 biosynthesis of, 130–132
 classification of, 80–111
 introduction to, 79–80
 natural occurrence of, 111–119
 newly isolated, 111, 120–124
 structure elucidation and stereochemistry, 124–126
 synthesis of, 126–131
Cycloposine, 199–200, 202
Cynoglossum officinale, toxic alkaloids of, 182–183
Cytisine, 169–172, 174–176
 IR and Raman spectroscopy of, 227–228
Cytisus scoparius, toxic alkaloids of, 171
Daechuine S3, 84, 112, 118
Daechuine S5, 88
Daechuine S6, 82, 112
Daechuine S7, 82, 112
Daechuine S8, 84, 112
Daechuine S10, 82
Daechuine S26, 82, 112
Daechuine S27, 135
Datura spp., toxic alkaloids of, 176–178
N-Deacetylflinaconitine, 23, 31, 44
 pharmacological activity of, 39, 68, 72
 plant sources of, 23, 27
N-Deacetylappaconitine
 classification and structure of, 13–14, 31–32, 37, 52–53
 pharmacological activity of, 39, 68, 71–73
 plant sources of, 13–14, 27–30
14-Deacetylindicaline, 192–194

- N*-Deacetylranaconitine
classification and structure of, 22–23,
31, 43
pharmacological activity of, 39, 68, 72
plant sources of, 22–23, 27, 29
- 2-Deacetyltaxine A, 197
- Death camas, toxic alkaloids of, 203–205
- Decaffeination, IR measurement of,
226–227
- 5,6-Dehydrolupanine, 170, 172, 174
- Delavaconine, 6, 31–32, 34, 46
plant sources of, 6, 27
- Delavaconitine, 8, 31, 35, 48–49
plant sources of, 8, 27
- Delavaconitine C, 7–8, 31, 34, 47–48
plant sources of, 7–8, 27
- Delavaconitine D, 7–8, 31, 34, 47–48
plant sources of, 7–8, 27
- Delavaconitine E, 8, 31, 35
plant sources of, 8, 27
- Delbine, 21, 31, 42, 60–61
plant sources of, 21, 30
- Delboxine, 25–26, 30, 31, 44, 66
plant sources of, 25–26
- Delphicrispuline, *see* Neofinaconitine
- Delphinium* spp., diterpene alkaloids in,
191–193
- Delphinium* spp., C₁₈-diterpenoid
alkaloids from, 5, 29–30
- Deltaline, 192, 194–195
- 14-*O*-Demethyldeboxine, 25–26, 31, 44,
66
plant sources of, 25–26, 30
- Demethylappaconitine
classification and structure of, 12, 31,
37, 52–53
plant sources of, 12, 28
- 14-Demethyltuguaconitine, 25, 32, 44, 65
plant sources of, 25, 30
- Density functional theory (DFT)
calculation
for anisodamine, 242
of opioid isoquinoline alkaloids,
232–233
for quinine, 236
for sanguinarine, 241
xanthine, caffeine, and theobromine
calculations using, 221, 224–225
- Deoxo-aralione A, 93, 117
- 6-Deoxy-6-*C*-(2,5-dihydroxyhexyl)-
DMDP, 146–147
- 7-Deoxy-6-*epi*-castanospermine, 160
- 9-Deoxy-6-methoxy-*N*-succinyl-
deacetylranaconitine
classification and structure of, 21–22,
32, 43
plant sources of, 21–22, 27
- 8-Deoxy-14-dehydroaconosine
classification and structure of, 7, 32, 34
plant sources of, 7, 29
- 1-Deoxyisotaxine B, 197
- 9-Deoxylappaconitine
classification and structure of, 11–12,
31–32, 37, 52–53
pharmacological activity of, 71
plant sources of, 11–12, 27–28
- 1-Deoxytaxine B, 196–197
- Desbenzoyl-aralione A, 93, 107, 118
- N*-Desmethyl-integerrinine, 93, 117
- N*-Desmethyl-integerrine, 93, 117
- O*-Desmethyl-mucronine D, 85, 112
- N*-Desmethyl-myrianthine B, 89, 117
- N*-Desmethyl-myrianthine C, 89, 119
- Devil's trumpet, toxic alkaloids of, 176
- DFT calculation, *see* Density functional
theory calculation
- 1,4-Dideoxy-1,4-imino-D-arabinitol,
146–147
- 2,5-Dideoxy-2,5-imino-DL-glycero-D-
manno-heptitol (Homo-DMDP),
146–147
- 2,3-Di-*epi*-australine, 160–161, 166–167
- 6,7-Di-*epi*-castanospermine, 160
- Dihydrocapsaicin, 251
- Dihydromonticamine, 9–10, 32, 36, 49–50
pharmacological activity of, 70
plant sources of, 9–10, 28
- Dihydroquinidine, 235–236
- Dihydroquinine, 235–236
- Dihydrosanguinarine, 188–190
- 2*R*,5*R*-Dihydroxymethyl-3*R*,4*R*-
dihydropyrrolidine (DMDP),
146–147
- Dioicine, 227–228
- Dioncopeltine A, 237–238
- Dioncophylline A, 237
- Dioncophylline C, 237
- Discarene C, 102, 109, 116, 125
- Discarene D, 102, 109, 116, 125–126
- Discaria* spp., cyclopeptide alkaloids
from, 116
- Discarine, 116
- Discarine A, 88, 116
- Discarine B, 88, 116, 117, 125–126

- Discarine C, 93, 116
 Discarine D, 93, 116, 125
 Discarine E, 88, 116
 Discarine F, 88, 116, 125
 Discarine G, 99, 116
 Discarine H, 99, 116
 Discarine I, 88, 116
 Discarine K, 99, 116, 126
 Discarine L, 99, 109, 116
 Discarine M, 102, 109, 116, 125
 Discarine N, 102, 109–110, 116, 125
 Discarine X, 88, 116
 Diterpene alkaloids
 IR and Raman spectroscopy of, 246–248
 larkspur, 191–196
 yew, 196–199
 C₂₀ Diterpenes, *see* Diterpene alkaloids
 C₁₈-Diterpenoid alkaloids, 1–73
 chemical reactions of, 30, 33, 67
 classification and structures of, 2–26, 30
 code numbers of, 30–33
 introduction to, 1–3
 NMR spectroscopy of, 5–26, 30
 occurrence of, 3–5
 pharmacological activity of, 3, 33, 39, 67–73
 analgesic, 39, 69
 anesthetic, 72
 antiarrhythmic, 69–72
 anti-inflammatory, 72
 plant sources of, 27–30
 C₁₉-Diterpenoid alkaloids,
 C₁₈-diterpenoid alkaloids v., 2
 DMDP, *see* 2*R*,5*R*-Dihydroxymethyl-
 3*R*,4*R*-dihydropyrrolidine
 Dolaconine, 7, 31–32, 34, 47–48
 plant sources of, 7, 27–29

 Echinatine, 183
Echium spp., toxic alkaloids of, 183
Embellisia, swainsonine production by,
 164
 English bluebell, toxic alkaloids of,
 146–147
 Episcopalisine, *see* Delavaconitine
 Episcopalinine, *see* Delavaconine
 Episcopalitine, *see* Dolaconine
Euonymus spp., cyclopeptide alkaloids
 from, 119
 Exceconidine, 18, 32, 40, 58–59
 plant sources of, 18, 27

 Excelsine, 15, 32, 38, 55–56
 isolation of, 2
 pharmacological activity of, 70
 plant sources of, 15, 27–29
 structure of, 2

 Fabaceae family, toxic alkaloids of,
 151–153, 158, 169–173
Feretia spp., cyclopeptide alkaloids from,
 119
 Feretine, 94, 119
 Finaconitine, 24, 32, 44, 63–64
 plant sources of, 24, 27, 29
 Formyl-nornicotine, 154
 Fourier transformed infrared and
 Raman spectroscopy, *see* Infrared
 and Raman spectroscopy
 Franganine, 88, 112, 115–117,
 119, 125
 Frangufoline, 88, 112–117, 119, 134–135
 cleavage of, 134–135
 Frangulanine, 88, 112–113, 116–119,
 131–133
 4(14)-Frangulanine type cyclopeptide
 alkaloids, 87–90, 106

 α -Galactosidase, calystegine inhibition
 of, 166–167
 β -Galactosidase, calystegine inhibition
 of, 166
 Gas chromatography (GC), for
 cyclopeptide alkaloid structure
 elucidation, 125
 GC, *see* Gas chromatography
 Germine, 199–200, 203
 α -Glucosidase inhibitors, 166–168
 β -Glucosidase inhibitors, 166–167
 Gramodendrine, 152–153

 Hartree–Fock method, xanthine,
 caffeine, and theobromine
 calculations using, 221
Heisteria spp., cyclopeptide alkaloids
 from, 119
 Heliosupine, 183
Heliotropium spp., toxic
 alkaloids of, 183
 Hemlock, *see* Poison hemlock
 Hemsine A, 95, 107, 118
 Hemsine B, 97, 108, 118
 Hemsine C, 94, 107, 118
 Hemsine D, 93, 107, 118

- Hepatotoxicity, of pyrrolizidine alkaloids, 185–187
- Heroin, 232–233*
- Hyspaconitine, 21–22, 32, 43, 60–61
 plant sources of, 21–22, 27
- Hohenackeridine, 25–26, 32, 44, 66
 plant sources of, 25–26, 30
- Homoamerecine, 89, 117
- Homo-capsaicin, 251
- Homo-dihydrocapsaicin, 251–252
- Homo-DMDP, *see* 2,5-Dideoxy-2,5-imino-DL-glycero-D-mannoheptitol
- Homo-DMDP-7-O- α -apioside, 146
- Homo-DMDP-7-O- β -D-xylopyranoside, 146–147
- Hovenia* spp., cyclopeptide alkaloids from, 118
- Hovenine A, 89, 118
- Human poisoning, 143–206
 by diterpene alkaloids
 larkspur, 191–196
 yew, 196–199
 by isoquinoline alkaloids, 188–190
 by piperidine alkaloids, 147–151
 by polyhydroxy indolizidine alkaloids and related pyrrolizidine and nortropane alkaloids, 158–169
 by pyridine alkaloids, 154–157
 by pyrrolidine alkaloids, 146–147
 by pyrrolizidine alkaloids, 179–187
 by quinolizidine alkaloids, 152–154, 169–176
 by steroidal alkaloids
 Veratrum alkaloids, 199–202
 Zigadenus alkaloids, 203–205
 by tropane alkaloids, 176–179
- Hyacinthacine B₁, 161
- Hyacinthacine C₁, 161
- Hyacinthoides non-scripta*, toxic alkaloids of, 146–147, 161
- 13-Hydroxylupanine, 246–248
- 10-Hydroxyranaconitine, classification and structure of, 32
- 10 β -Hydroxyranaconitine, *see* Finaconitine
- 13-Hydroxysparteine, 246–248
- Hymenocardia* spp., cyclopeptide alkaloids from, 119
- Hymenocardine, 103, 119
- L-Hyoscyamine, 176–179
- Hyoscyamus niger*, toxic alkaloids of, 176–178
- Hysodricanine A, 97, 112, 115
- Ibogaine hydroxyindolenine, 248–249
- Indole alkaloids, *see* Monoterpenoid indole alkaloids
- Indolizidine alkaloids, *see* Polyhydroxy indolizidine alkaloids
- Indolizidines, IR spectroscopy of, 219
- Infrared (IR) and Raman spectroscopy, 217–253
 of antimalarial isoquinoline and naphthylisoquinoline alkaloids, 234–239
 of benzylisoquinoline alkaloids, 239–241
 conclusions on, 252–253
 introduction to, 218–219
 of monoterpenoid indole alkaloids, 248–251
 of natural isoquinoline alkaloid dyes, 233–234
 of nitrogen bridgehead compounds, 219–220
 of opioid isoquinoline alkaloids, 228–233
 of piperidine alkaloids, 244–245
 of protoalkaloids, 251–252
 of purine alkaloids, 220–228
 of pyrrolidine alkaloids, 243–244
 of quinolizidine alkaloids, 246–248
 of tropane alkaloids, 241–242
- Infra-red Band assignments
 of berberine, 234
 of caffeine, 221–223
 of capsaicin, 251–252
 of chelerythrine, 239
 of cocaine, 233
 of codeine, 230–231
 of dioicine, 227–228
 of isotetrandrine, 240
 of lupines, 248
 of monoterpenoid indole alkaloids, 249
 of morphine, 230–233
 of naphthylisoquinoline alkaloids, 237–238
 of nicotine, 243–244
 of noscapine, 230–231
 of opioid isoquinoline alkaloids, 230–231
 of papaverine, 231–232
 of piperine, 244–245

- of quinidine, 236
- of quinine, 236
- of sanguinarine, 239–241
- of scopolamine, 242
- of thebaine, 230–231
- of theobromine, 221–224
- of theophylline, 221–223
- Integerrenine, 93, 113, 117, 119
- Integerressine, 93, 117
- Integerrimine, 180, 184
- Integerrine, 93, 117
- 4(14)-Integerrine type cyclopeptide alkaloids, 92–93, 107
- Ipomoea* spp., toxic alkaloids of, 159, 162–167
- IR spectroscopy, *see* Infrared and Raman spectroscopy
- Isolappaconitine
 - classification and structure of, 22–23, 32, 43, 62–63
 - pharmacological activity of, 71
 - plant sources of, 22–23, 27–28
- Isolupanine, 246
- Isoquinoline alkaloids, 188–190
 - IR and Raman spectroscopy of, 228–233
 - antimalarial alkaloids, 234–239
 - natural isoquinoline alkaloid dyes, 233–234
 - opioid alkaloids, 228–233
- Isotaxine B, 196–197
- Isotetrandrine, 240–241
- Jacobine, 182
- Jaconine, 182
- Jervanines, 202
- Jervine, 199–200, 202
- Jimson weed, toxic alkaloids of, 176, 178
- Jubanine A, 84, 113, 114, 115
- Jubanine B, 84, 113, 114
- Jubanine C, 94, 107, 114
- Kiramine, 11, 32, 36
 - plant sources of, 11, 28
- Kiridine, 16, 32, 38, 55–56
 - plant sources of, 16, 28
- Kiritine, 16, 32, 39
 - plant sources of, 16, 28
- Laburnum anagyroides*, toxic alkaloids of, 171, 174
- Lamarckinine, 20, 32, 42, 59–60
 - plant sources of, 20, 28
- Lappaconidine, 9–10, 32, 36, 49–50
 - isolation of, 2
 - pharmacological activity of, 71
 - plant sources of, 9–10, 28–29
 - structure of, 2
- Lappaconine
 - classification and structure of, 9–10, 32, 36, 49–50
 - pharmacological activity of, 70
 - plant sources of, 9–10, 28
- Lappaconine-subtype
 - classification and structure of, 36–39, 49–56
 - classification of, 3–5, 9–16
 - structure of, 4
- Lappaconitine
 - classification and structure of, 13–14, 32, 38, 53–54
 - isolation of, 1
 - pharmacological activity of, 3, 39, 67–73
 - plant sources of, 13–14, 27–30
 - structure of, 2
- Lappaconitine-type
 - classification and structure of, 34–35, 46–56
 - classification of, 3–5, 6–16
- Larkspur alkaloids, *see* Diterpene alkaloids
- Lasiocarpine, 180–181
- Lasiodine A, 103, 118
- Lasiodine B, 91, 118
- Lasiodiscus* spp., cyclopeptide alkaloids from, 118
- Lentiginosine, 158, 160
- 2-*epi*-Lentiginosine, 158
- Leuconine
 - classification and structure of, 17, 32, 40, 57
 - plant sources of, 17, 28–29
- Leuconine-subtype
 - classification and structure of, 40–42, 57–60
 - classification of, 3–5, 17–20
 - structure of, 4
- Leucostine, 17, 32, 40, 57
 - plant sources of, 17, 28–29
- Liconosine A, 9, 32, 35, 48–49
 - plant sources of, 9, 28
- Linearilin, 21, 32, 42–43, 60–61
 - plant sources of, 21, 30

- Livestock poisoning, 143–206
by bipiperidine alkaloids, 151–154
conclusions and outlook on, 206
by diterpene alkaloids
larkspur, 191–196
yew, 196–199
introduction to, 144–146
by isoquinoline alkaloids, 188–190
by piperidine alkaloids, 147–151
by polyhydroxy indolizidine alkaloids and related pyrrolizidine and nortropane alkaloids, 158–169
by pyridine alkaloids, 154–157
by pyrrolidine alkaloids, 146–147
by pyrrolizidine alkaloids, 179–187
by quinolizidine alkaloids, 152–154, 169–176
by steroidal alkaloids
Veratrum alkaloids, 199–202
Zigadenus alkaloids, 203–205
by tropane alkaloids, 176–179
Lobelia berlandieri, toxic alkaloids of, 149–151
Lobeline, 149
Lochnerine, 249–250
Locoweeds, 158–160, 163–166, 176
Lotusanine B, 102, 110, 112
Lotusine A, 95, 112, 118
Lotusine B, 98, 108, 112
Lotusine C, 98, 112
Lotusine D, 95, 112, 118
Lotusine E, 85, 112
Lotusine F, 82, 112
Lotusine G, 95, 107, 112
Lupanine, 169–172, 174–176
IR and Raman spectroscopy of, 246–247
Lupines
IR and Raman spectroscopy of, 246–248
livestock toxicity of, 151–154, 169–175
Lupinine, 169–170
Lupinus spp., toxic alkaloids of, 151–153, 169–175
Lycoctonine, 192, 194–195
ranaconitine v., 3
Lycopsamine, 180–181
Mahonia beali, medicinal alkaloids of, 240
 α -Mannosidase, swainsonine inhibition of, 165–166
Mass spectrometry (MS), for
cyclopeptide alkaloid structure elucidation, 124
Matrine, 169–170, 172, 176
Mauritine A, 98, 113, 114, 115, 127
Mauritine B, 98, 115, 127
Mauritine C, 96, 113, 115, 127
Mauritine D, 98, 113, 114, 115
Mauritine E, 98, 115
Mauritine F, 98, 113, 115, 127
Mauritine H, 98, 115
Mauritine J, 98, 108, 115
Mauritine K, 98, 109, 115, 122, 133
MDL, *see* 7,8-Methylenedioxy lycoctonine
Mechanisms of action, *see*
Structure–activity relationships and mechanisms of action
Melochia spp., cyclopeptide alkaloids from, 119
Melofoline, 89, 119
Melonovine A, 89, 112, 119
Melonovine B, 89, 119
Metarhizium anisopliae, 159
N-Methyl-amicine, 89, 117
N-Methylammodendrine, 151–153, 170
N-Methylcalystegine C₁, 162
N-Methylconiine, 147–148, 150
N-Methylcytisine, 170–172, 174
7,8-Methylenedioxy lycoctonine (MDL), 192, 194
Methyllycaconitine (MLA), 192–195
N-(Methylsuccinyl)anthranoyl lycoctonine (MSAL) alkaloids, 192, 194
6-O-Methylumbrofine, *see* Exceconidine
Mid-infrared spectroscopy, *see* Infrared and Raman spectroscopy
MLA, *see* Methyllycaconitine
Monocrotaline, 180, 184–186
Monoterpenoid indole alkaloids, IR and Raman spectroscopy of, 248–251
Monticamine, 14–15, 32, 38, 53–54
pharmacological activity of, 70
plant sources of, 14–15, 28
Monticoline, 24, 32, 44, 65
pharmacological activity of, 70
plant sources of, 24, 28
Moreton Bay Chestnut, toxic alkaloids of, 160–161, 164–169
Morphine, 228–233
MS, *see* Mass spectrometry

- MSAL alkaloids, *see*
N-(Methylsuccinyl)anthranoyl
 lycoctonine alkaloids
- Mucronine A, 101, 112, 115
- 4(15)-Mucronine A type cyclopeptide
 alkaloids, 100–101
- Mucronine B, 101, 112, 115, 126–127
- Mucronine C, 101, 112, 115
- Mucronine D, 85, 112–114
- Mucronine E, 101, 112, 127, 129
 synthesis of, 129–130
- Mucronine F, 101, 112
- Mucronine G, 101, 112
- Mucronine H, 101, 112
- Mucronine J, 96, 108, 112, 118
- Myrianthine A, 93, 116, 119
- Myrianthine C, 89, 119
- Myrianthus* spp., cyclopeptide alkaloids
 from, 119
- nAChRs, *see* Nicotinic acetylcholine
 receptors
- Na⁺-K⁺-ATPase inhibition, by
 isoquinoline alkaloids, 190
- Naphthylisoquinoline alkaloids,
 antimalarial alkaloids, 234–239
- Natural isoquinoline alkaloid dyes, IR
 and Raman spectroscopy of,
 233–234
- Near-infrared spectroscopy, *see* Infrared
 and Raman spectroscopy
- Necic acids, 179–180
- Necine base, of pyrrolizidine alkaloids,
 179–187
- Neofinaconitine, 11–12, 31–32, 36, 50–51
 plant sources of, 11–12, 27, 30
- Neostigmine, 195
- Neutral cyclopeptides, 102, 109–110
- Nicotiana* spp., toxic alkaloids in,
 154–157
- Nicotinamide, 244
- Nicotine, 227–228, 243–244
- S-(–)-Nicotine, 154–157
- Nicotinic acetylcholine receptors
 (nAChRs), nicotine and related
 alkaloid effects on, 156–157
- Nitrogen bridgehead compounds, IR
 spectroscopy of, 219–220
- NMR, *see* Nuclear magnetic resonance
 spectroscopy
- ¹H NMR, *see* ¹H Nuclear magnetic
 resonance spectroscopy
- ¹³C NMR, *see* ¹³C Nuclear magnetic
 resonance spectroscopy
- Nor-dihydrocapsaicin, 251
- Norditerpenes, 191–196
 plant spp. and specific alkaloids,
 191–193
 structure-activity relationships and
 mode of action of, 194–196
 toxicity and clinical signs of, 193–194
- C₁₉ Norditerpenes, *see* Norditerpenes
- Norditerpenoid alkaloids, *see*
 C₁₈-Diterpenoid alkaloids
- S-(–)-Nornicotine, 154, 157
- Nortropane alkaloids, 158–169
 plant spp. and specific alkaloids,
 158–163
 structure-activity relationships and
 mode of action of, 165–169
 toxicity and clinical signs of, 163–165
- Noscapine, 229–231
- ¹H Nuclear magnetic resonance
 spectroscopy (¹H NMR)
 for aconosine-subtype alkaloids, 6–9,
 34–35
 for lappaconine-subtype alkaloids,
 9–16, 36–39
 for leuconine-subtype alkaloids,
 17–20, 40–42
 for ranaconitine-subtype alkaloids,
 21–26, 42–45
- ¹³C Nuclear magnetic resonance
 spectroscopy (¹³C NMR)
 for aconosine-subtype alkaloids, 6–9,
 46–49
 for lappaconine-subtype alkaloids,
 9–16, 49–56
 for leuconine-subtype alkaloids,
 17–20, 57–60
 for ranaconitine-subtype alkaloids,
 21–26, 60–66
- Nuclear magnetic resonance
 spectroscopy (NMR), for
 cyclopeptide alkaloid structure
 elucidation, 124–126
- Nudicaline, 192–194
- Nummularine, 83
- Nummularine A, 85, 113–114
- Nummularine B, 85, 112–114
- Nummularine C, 83, 112
- 4(13)-Nummularine C type cyclopeptide
 alkaloids, 82–83, 104
- Nummularine D, 93, 113

- Nummularine E, 93, 113, 115
Nummularine F, 96, 113
Nummularine G, 103, 113
Nummularine H, 85, 113, 118, 135
Nummularine K, 89, 113–114
Nummularine M, 93, 113
Nummularine N, 85, 113
Nummularine O, 85, 113
Nummularine P, 85, 113–114
Nummularine R, 83, 112–113, 115
Nummularine S, 83, 113
Nummularine S10, 83, 113
Nummularine T, 85, 113
- Obovamine, 249
Obovatine, 249
Opioid alkaloids, 188–190
 IR and Raman spectroscopy of, 228–233
Otonocene, 179
N-Oxides
 of nicotine, 154
 of pyrrolizidine alkaloids, 181–186
Oxyphylline A, 94, 107, 115, 122
Oxytropis spp., toxic alkaloids in,
 158–160, 163–164
- Paclitaxel, *see* Taxol
Paliurine A, 85, 104, 118
Paliurine B, 85, 104, 118
Paliurine C, 85, 104, 118
Paliurine D, 85, 104–105, 118
Paliurine E, 83, 104, 112, 118, 126, 129
Paliurine F, 85, 105, 118
Paliurine G, 85, 105, 118
Paliurine H, 86, 105, 118
Paliurine I, 86, 105, 118
Paliurus spp., cyclopeptide alkaloids
 from, 118
Panda spp., cyclopeptide alkaloids from,
 119
Pandamine, 99, 119
4(14)-Pandamine type cyclopeptide
 alkaloids, 99, 109
Pandaminine, 99, 119
Papaveraceae family, toxic alkaloids of,
 188–190, 228–233
Papaverine, 229, 231–232
Para-cyclophanes, synthesis of, 127
Partial least squares (PLS)
 of caffeine and theobromine, 227
 of cocaine, 242
 of heroin, 232–233
 of nicotine, 243
 of quinine and quinidine, 237
Paulirine E, synthesis of, 130–131
PCR, *see* Principal component regression
Pepper alkaloids, IR and Raman
 spectroscopy of, 244–245
Pharmacological activity
 of cyclopeptide alkaloids, 131–135
 antimicrobial, 133
 antispasmodic, 133
 sedative, 134
 of C₁₈-diterpenoid alkaloids, 3, 33, 39,
 67–73
 analgesic, 39, 69
 anesthetic, 72
 antiarrhythmic, 69–72
 anti-inflammatory, 72
Physostigmine, 195
Piepunendine A, 9, 32, 35, 48–49
 plant sources of, 9, 28
Piepunendine B, 35, 47–48
 plant sources of, 7–8, 28
 Δ^3 -Piperidine, 149, 151
Piperidine alkaloids, 147–151
 IR and Raman spectroscopy of,
 244–245
Piperine, 244–245
Plant alkaloids, IR and Raman
 spectroscopy of, 217–253
 antimalarial isoquinoline and
 naphthylisoquinoline alkaloids,
 234–239
 benzylisoquinoline alkaloids,
 239–241
 conclusions on, 252–253
 introduction to, 218–219
 monoterpenoid indole alkaloids,
 248–251
 natural isoquinoline alkaloid dyes,
 233–234
 nitrogen bridgehead compounds,
 219–220
 opioid isoquinoline alkaloids, 228–233
 piperidine alkaloids, 244–245
 protoalkaloids, 251–252
 purine alkaloids, 220–228
 pyrrolidine alkaloids, 243–244
 quinolizidine alkaloids, 246–248
 tropane alkaloids, 241–242
Plant sources
 of cyclopeptide alkaloids, 111–119
 of C₁₈-diterpenoid alkaloids, 6–30

- Platynecine, 180
(-)-Platynecine, 179
Plectronia spp., cyclopeptide alkaloids from, 119
PLS, *see* Partial least squares
Poison hemlock, toxic alkaloids of, 147–151
Poisonous plant spp., 144–145
 bipiperidine alkaloids in, 151–152
 diterpene alkaloids in, 191–193, 196–197
 isoquinoline alkaloids in, 188–189
 piperidine alkaloids in, 147–149
 polyhydroxy indolizidine alkaloids and related pyrrolizidine and nortropane alkaloids in, 158–163
 pyridine alkaloids in, 154–155
 pyrrolidine alkaloids in, 146–147
 pyrrolizidine alkaloids in, 179–184
 quinolizidine alkaloids in, 169–172
 steroidal (*Veratrum*) alkaloids in, 199–200
 steroidal (*Zigadenus*) alkaloids in, 203–204
 tropane alkaloids in, 176–178
Polyhydroxy alkaloid glycosidase inhibitors, 166–168
Polyhydroxy indolizidine alkaloids, 158–169
 plant spp. and specific alkaloids, 158–163
 structure-activity relationships and mode of action of, 165–169
 toxicity and clinical signs of, 163–165
Polyhydroxy nortropanes, *see* Calystegines
Poppy family, toxic alkaloids of, 188–190, 228–233
Principal component regression (PCR), of quinine and quinidine, 237
Protoalkaloids, IR and Raman spectroscopy of, 251–252
Protopine, 188–190
(2*S*,5*S*)-(+)-Pseudoconhydrine, 147–148
Puberanidine, *see* *N*-Deacetylappaconitine
Puberanine, 32, 43–44, 62–63
Pubescine A, 89, 116
Purine alkaloids, IR and Raman spectroscopy of, 220–228
Pyridine alkaloids, 154–157
Pyrrole, metabolic pathway creating, 186–187
Pyrrolidine alkaloids, 146–147
 IR and Raman spectroscopy of, 243–244
Pyrrolizidine alkaloids, 158–169, 179–187
 plant spp. and specific alkaloids, 158–163, 179–184
 structure-activity relationships and mode of action of, 165–169, 185–187
 toxicity and clinical signs of, 163–165, 184–185
Pyrrolizidines, IR spectroscopy of, 219
Quinidine, 235–237
Quinine, 234–237
Quinoline ring, 236
Quinolizidine alkaloids, 152–154, 169–176, 219–220
 IR and Raman spectroscopy of, 246–248
 plant spp. and specific alkaloids, 169–172
 structure-activity relationships and mode of action of, 174–176
 toxicity and clinical signs of, 173–174
Raman mapping, 218–219
 of benzyloisoquinoline alkaloids, 239–241
Raman spectroscopy, *see* Infrared and Raman spectroscopy
Ramosine A, 96, 108, 118
Ramosine B, 98, 109, 118
Ramosine C, 96, 108, 118
Ranaconitine
 classification and structure of, 22–23, 33, 43, 62–63
 pharmacological activity of, 39, 68, 71–72
 plant sources of, 22–23, 27–29
Ranaconitine-subtype
 classification and structure of, 42–45, 60–66
 classification of, 3–5, 21–26
 structure of, 4
Red pepper, alkaloids in, 251–252
Reticuline, 188–189
(+)-Retronecine, 179
Retrorsine, 182

- Rhamnus* spp., cyclopeptide alkaloids from, 117
- Rhizoctonia leguminicola*, 159
- Rhombifoline, 172
- Riddelline, 180, 182, 186–187
- Rivularine, *see* 7-Angelyl heliotridine
- Robusta coffee beans, quantification of caffeine in, 225
- Rubijervine, 199–200
- Rugosanine A, 86, 113
- Rugosanine B, 83, 113
- Sanguinarine, 188–190
IR and Raman spectroscopy of, 239–241
- Sanjoinine, 102, 112, 115
- Sanjoinine A, *see* Frangufoline
- Sanjoinine B, 89, 115
- Sanjoinine D, 99, 115, 134
- Sanjoinine F, 89, 112, 115, 135
- Sanjoinine G1, 99, 115, 127
- Sanjoinine G2, 103, 115, 134–135
- Sativanine A, 93, 113, 115
- Sativanine B, 103, 113
- Sativanine C, 86, 113
- Sativanine D, 103, 113
- Sativanine E, 83
- Sativanine F, 86, 113
- Sativanine G, 83, 113, 118
- Sativanine H, 86, 113
- Sativanine K, 83, 113, 115
- Sativanine M, 86, 105, 114, 121
- Sativanine N, 83, 104, 114, 120
- Sativanine O, 83, 104, 114, 120
- Scilla non-scripta*, toxic alkaloids of, 146–147
- Scopaline, 6, 33, 34, 46
plant sources of, 6, 27
- Scopolamine, 176–179
IR and Raman spectroscopy of, 242
- Scotch broom, toxic alkaloids of, 171
- Scutia* spp., cyclopeptide alkaloids from, 116–117
- Scutianene C, 102, 117
- Scutianene D, 133
- Scutianine A, 91, 116–117, 125
- 5(14)-Scutianine A type cyclopeptide alkaloids, 91, 107
- Scutianine B, 89, 116–119, 125, 133
- Scutianine C, 89, 116–117, 119, 125, 133
- Scutianine D, 89, 113–114, 116–117, 124–126, 133
- Scutianine E, 89, 116–117, 124–126, 133
- Scutianine F, 91, 117, 133
- Scutianine G, 90, 116
- Scutianine H, 90, 117, 125
- Scutianine J, 90, 106, 117
- Scutianine K, 90, 106, 117, 126
- Scutianine L, 93, 117, 124, 126
- Scutianine M, 93, 117, 124, 126, 133
- Sedative activity, of cyclopeptide alkaloids, 134
- Senecio* spp., toxic alkaloids of, 181–182, 186
- Senecionine, 180, 182
- Seneciphylline, 182
- Senkirkine, 180
- Sepaconitine, 14–15, 33, 38, 53–54
pharmacological activity of, 71
plant sources of, 14–15, 28–29
- Septeine, 12, 33, 37
plant sources of, 12, 29
- SERS, *see* Surface-enhanced Raman scattering
- Sida carpinifolia*, toxic alkaloids of, 159
- Sinomontanine A, 13–14, 33, 38, 53–54
plant sources of, 13–14, 29
- Sinomontanine B, 12, 33, 37, 52–53
plant sources of, 12, 29
- Sinomontanine D, 21, 33, 42, 60–61
plant sources of, 21, 29
- Sinomontanine E, 10, 33, 36, 49–50
plant sources of, 10, 29
- Sinomontanine F, 23, 33, 44, 63–64
plant sources of, 23, 29
- Sinomontanine G, 24, 33, 44, 63–64
plant sources of, 24, 29
- Sinomontanine H, 21–22, 33, 43, 60–61
plant sources of, 21–22, 29
- Slaframmine, 159
- Solanidines, 201–202
- (-)-Sophocarpine, 172
- Sophora* spp., toxic alkaloids of, 171–172
- Sparteine, 169–172, 174–176
IR and Raman spectroscopy of, 227–228, 246
- Spectabiline, 180, 184
- Sphaeranthus* spp., cyclopeptide alkaloids from, 119
- Spinanine A, 96, 115
- Stem bark, 113
- Steroidal alkaloids
Veratrum alkaloids, 199–202
Zigadenus alkaloids, 203–205

- Stokes lines, 218
- Structure-activity relationships and mechanisms of action
- of diterpene alkaloids, 194–196, 198–199
 - of isoquinoline alkaloids, 190
 - of piperidine alkaloids, 149–150
 - of polyhydroxy indolizidine alkaloids and related pyrrolizidine and nortropane alkaloids, 165–169
 - of pyridine alkaloids, 156–157
 - of pyrrolidine alkaloids, 147
 - of pyrrolizidine alkaloids, 185–187
 - of steroidal (*Veratrum*) alkaloids, 202
 - of steroidal (*Zigadenus*) alkaloids, 205
 - of tropane alkaloids, 178–179
- Subfraction I, 83, 119
- Subfraction II, 83, 119
- Surface-enhanced Raman scattering (SERS), 218
- of berberine, 234
 - of caffeine, 224–225
 - of chelerythrine, 239
 - of cocaine, 242
 - of nicotine, 244
 - of opioid isoquinoline alkaloids, 232
 - of sanguinarine, 239–241
- Swainsona* spp., toxic alkaloids of, 158, 164–165
- Swainsonine, 158–160, 163–169
- Symphytum* spp., toxic alkaloids of, 183
- Synthesis, of cyclopeptide alkaloids, 126–131
- Taxicins, 197
- Taxines, 197–198
- Taxol (Paclitaxel), 197
- Taxus* spp., diterpene alkaloids in, 196–197
- Tea, IR measurement of caffeine in, 226–227
- Texensine, 90, 117
- Thebaine, 229–231
- Theobromine, 220–224, 227
- Theophylline, 220–224, 227
- Thermopsine, 172, 174
- Thermopsis* spp., toxic alkaloids of, 172, 174, 176
- Thorn apple, toxic alkaloids of, 176
- Tiantaishansine, 25, 33, 44, 65
- plant sources of, 25, 30
- Tobacco plants
- IR and Raman measurement of alkaloids in, 243–244
 - toxic alkaloids in, 154–157
- Toxicity
- of bipiperidine alkaloids, 153
 - of diterpene alkaloids, 193–194, 197–198
 - of isoquinoline alkaloids, 189–190
 - of piperidine alkaloids, 149–150
 - of polyhydroxy indolizidine alkaloids and related pyrrolizidine and nortropane alkaloids, 163–165
 - of pyridine alkaloids, 155–156
 - of pyrrolidine alkaloids, 147
 - of pyrrolizidine alkaloids, 184–185
 - of steroidal (*Veratrum*) alkaloids, 201
 - of steroidal (*Zigadenus*) alkaloids, 204–205
 - of tropane alkaloids, 178
- 2,3,7-Tri-*epi*-australine, 160–161, 166–167
- Triphyophyllum pelatatum*, antimalarial alkaloids of, 237
- Tropane alkaloids, 176–179
- IR and Raman spectroscopy of, 241–242
- Tscheschamine, 83, 113
- Tuguaconitine, 25, 33, 44
- plant sources of, 25, 29
- Turbina cordata*, toxic alkaloids of, 159
- Ugi-four component reaction (Ugi-4CR), 127
- Umbrofine, 17–18, 33, 40, 57
- plant sources of, 17–18, 29
- Usaramine, 184
- UV resonance Raman microspectroscopy
- of quinidine, 236
 - of quinine, 236
- VCD spectroscopy, *see* Vibrational circular dichroism spectroscopy
- Veratramine, 199–200
- Veratrines, 202
- Veratrum* alkaloids, *see* Steroidal alkaloids
- Vibrational circular dichroism (VCD) spectroscopy, of anisodamine, 242
- Vibrational spectral assignments, *see* Infra-red Band assignments

- Vigna* spp., cyclopeptide alkaloids from, 119
- Vignatic acid A, 103, 110, 119
- Vignatic acid B, 103, 110, 119
- Voacangine acetoxyindolenine, 248–249
- Voacangine hydroxyindolenine, 248–249
- Waltheria* spp., cyclopeptide alkaloids from, 118
- Waltherine A, 90, 106, 118
- Waltherine B, 90, 106, 118
- Waltherine C, 90, 106, 118
- Wild indigos, toxic alkaloids of, 171
- Xanthine, 220–221, 227
- Xylopyrine A, 83, 104, 114
- Xylopyrine B, 83, 104, 114, 121
- Yew alkaloids, *see* Diterpene alkaloids
- Yohimbine, 248–251
- Yohimbines, IR spectroscopy of, 219
- Zigadenus* alkaloids, *see* Steroidal alkaloids
- Zizyphine A, 86, 114, 126–127
- 5(13)-Zizyphine A type cyclopeptide alkaloids, 84–86, 104–106
- Zizyphine B, 86, 114
- Zizyphine C, 86, 114
- Zizyphine D, 101, 114
- Zizyphine E, 101, 114
- Zizyphine F, 86, 114–115
- Zizyphine G, 96, 114
- Zizyphine I, 86, 114
- Zizyphine K, 86, 114
- Zizyphine N, 86, 105, 115, 126, 133
- synthesis of, 127–128
- Zizyphine O, 86, 105, 115, 133
- Zizyphine P, 86, 105, 115, 133
- Zizyphine Q, 86, 105–106, 115, 133
- Zizyphus* spp.
- cyclopeptide alkaloids from, 112–115
- pharmacological activities of, 131, 133–134
- Zygacine, 202–204
- Zygadenine, 203

- 3-*O*-Acetyllycoramine, 11f
 2-*O*-Acetyllycorine, antiplasmodial activity of, 33
 1-*O*-Acetyl-8-norpluviine, 9f
N-Acetypachypodanthine, 93t, 99t, 113
 Agar-solidified medium, *L. aestivum* cultivation on, 220
 7-Alkyl-6a7-didehydroaporphines, 112f
 Alzheimer's disease, galanthamine treatment of, 20
 history of, 161t
 mechanism of action, 163–164
Amaryllidaceae alkaloids
 biosynthesis of, 3
 classification of, 2–3
 NMR of, 13–15
 in *Pancreatium* spp., distribution by type, 13t
 synthetic studies of, 18
Amaryllidaceae spp., distribution of, 2, 2f
 Aminoethylphenanthrenes, 100t, 106f, 115f, 114–115
 pharmacology of, 144–145
 antimicrobial activity of, 142
 Anobine, 89t, 96t
 Anonaine, 96t
 antimicrobial activity of, 142
 antiplasmodial activity of, 142
 cytotoxicity of, 141
 pharmacology of, 139
 sources of, 87t, 90t, 128
 Antifeedant activity of *Erythrina latissima* alkaloids, 42
 Antileishmania activity of *Duguetia* alkaloids, 142
 Antimovo population of *L. aestivum*, 178t, 193f
 Antiplasmodial activity
 of *Duguetia* alkaloids, 137, 143
 of *Pancreatium* alkaloids, 33
 Antiproliferative activity, of *Pancreatium* alkaloids, 31t
 Anxiolytic effects, of crude *Erythrina* alkaloids, 43
 Apoptosis, *Pancreatium* alkaloid induction of, 31t, 32
 Aporphines, 95–97t, 105f, 109–114
 alkaloids related to, 119–122
 chemistry of, 117–119
 formation of, 126–127
 pharmacology of, 139–143
 Archar population, of *L. aestivum*, 178t
Argemone mexicana, alkaloids of, 125
 Argenaxine, 125
 Arkutino population of *L. aestivum*, 175f, 176–177t, 193f
 Aromatic compounds, in *Duguetia* spp., 84
 Artabotrine. *See* Isocorydine
 Asimilobine, 87t, 95t
 antiplasmodial activity of, 143
 pharmacology of, 140–141
 Atherospermidine, 100t
 biogenesis of, 128
 pharmacology of, 143
 sources of, 87t
 Atherosperminine
 pharmacology of, 144–145
 sources of, 88t, 90t, 114–115, 131
 Atherosperminine-*N*-oxide, 115
 Augustine, synthesis of, 23f
 Auxins, treatment of *L. aestivum* cultures with, 234, 235f
 Azaanthraquinone, 106f, 101t, 116f
 isolation of, 116
 pharmacology of, 146
 1-Azaaporphinoids, *See* Copyrine alkaloids, 115
 1-Aza-4,5-dioxoaporphine, 106f
 Azahomoaporphines, 106f, 101t, 116f
 biogenesis of, 130
 isolation of, 116
 1-Aza-7-oxoaporphine, 106f
 Aza-Wittig reaction in *Erythrina* alkaloid synthesis, 74
 Baltata population of *L. aestivum*, 178t
 Benzylisoquinolines, 94t, 105t, 106f
 chemistry of, 117
 from *Duguetia* spp., 84
 from magnoliids, 85

- pharmacology of, 133–134
 1-Benzyl-tetrahydroisoquinolines. *See*
 Benzylisoquinolines
 Berberine bridge enzyme, 124
 Berberine, biosynthesis of, 124
 Berbines, 94–95t, 105f
 alkaloids related to, 119–122
 biosynthesis of, 124
 chemistry of, 117
 distribution of, 107
 isolation of, 107–109
 pharmacology of, 134–137
 Bio Music 6 in 1 process, effect on
 L. aestivum growth, 258
 Biogenesis
 of azahomoaporphines, 130
 of copyrine alkaloids, 129
 of *Duguetia* alkaloids, 122–131
 of spiduxine, 125f
 Biological clock, of *L. aestivum*
 jasmonic acid effect on, 235
 as regulatory mechanism for alkaloid
 synthesis, 203–204
 Biosynthesis. *See also* Galanthamine
 biosynthesis
 of *Amaryllidaceae* alkaloids, 3
 of berberine, 124
 of berbines, 124
 of crinine, 5f
 3,4-dihydroxybenzaldehyde in, 3, 4f
 of *Duguetia* alkaloids, 122–131
 of erythraline, 42f
 of *Erythrina* alkaloids, aromatic, 41–42
 of *Erythrina* alkaloids, non-aromatic, 67
 of 1-O- β -D-glycosillicorine, 9f
 lycorenine, 5f
 of lycorine, 5f, 9f
 of 4'-O-methylnorbelladine, 4f
 of montanine, 6
 music influence on, 260f, 263–265
 of narciclasine, 6
 of norbelladine, 3, 4f
 of norpluviine, 9f
 norpluviine in, 5f, 9f
 of tazettine, 4, 6f
 tyramine in, 3, 4f
 Bisbenzylisoquinoline, 94t, 105f
 pharmacology of, 134
 Bisbenzyltetrahydroisoquinolines, 106f
 chemistry of, 117
 Blatoto population of *L. aestivum*, 175f,
 176–177t, 193f
 Boldine, chemistry of, 128
 Brunsvigine, 29f
Bryophyllum daigremontianum, circadian
 rhythm of, 206
 Buphanisine, 12f
 apoptosis induction by, 31t
 cytotoxicity of, 31t
 Buxifoline, 89t, 96t

Calothrix, spp., alkaloids isolated from,
 91t
 Calycine, 88–89t, 91t, 97t
Campotheca acuminata, precursor
 feeding to, 244
 Canadine oxidase, 124
 Cancer proliferation, *Pancreas*
 alkaloids effect on, 31–33, 31t
Catharanthus roseus, precursor feeding to,
 244
 Chalcones in *Pancreas* spp., 12
 Chemosystematics of *Duguetia* spp.,
 122–131
 Cholinergic hypothesis, 163
 Cholinesterase inhibitors, 163
 Chromones in *Pancreas* spp., 12
 Circadian rhythm, of *Bryophyllum*
 daigremontianum, 206
 Cleistopholine, 91t, 101t, 116, 130
 antimicrobial activity of, 146
 antiplasmodial activity of, 146
 cytotoxicity of, 146
 Cocculolidine, 67f
 insecticidal activity of, 68
 synthesis of, 67–70
Cocculus laurifolius, alkaloid biosynthesis
 in, 125
 Codamine-cis-N-oxide, 123
 Convulsions, *Erythrina* alkaloids in
 control of, 44
Coptis japonica, enzymes from, 126
 Copyrine alkaloids, 101t, 115
 biogenesis of, 129
 pharmacology of, 145–146
 Coreximine, 124–125
Corydalis racemosa, 123
 Corypalmine, 88t, 92–94t, 124
 from staudine, 121
 Corytenchine, 124
 Corytuberine, 126
 Crinamine, 13f
 antiplasmodial activity of, 33
 Crinan-3-one, 12f

- Crinine, 3f, 12f, 14t
absolute configuration of, 18f
apoptosis induction by, 31t
biosynthesis of, 5f
cytotoxicity of, 31t
NMR characteristics of, 18
in *Pancreaticum* spp., 12
synthesis of, 23–24, 25f
- Crinum macowanii*, alkaloid variation in, 207
- Curare-like activity of *Erythrina latissima*, 43
- Cyclization
in erythrinan ring formation, 55–62
Heck reaction, in *Erythrina* alkaloid synthesis, 73
methods of, 55–62
of methylthio amides, 52
in montanine synthesis, 27
Pummerer reaction, in *Erythrina* alkaloid synthesis, 58
spiro-reaction, in *Erythrina* alkaloid synthesis, 50
- Cytokinins, alkaloid production in *L. aestivum* cultures with, 234, 235f
- Dehydroaporphines, 97t
- Dehydrodiscretine, 87t, 95t
- 3-Demethoxyerythratidinone, synthesis of 50, 51f, 52–54, 55f, 59, 60f
- 9-O-Demethylhomolycorine, 8f
- Demethylmaritidine, 13f
apoptosis induction by, 31t
cytotoxicity of, 31t
- 10-Demethylxylopinine, 88t, 95t
- 6-Deoxytazettine, in *Pancreaticum* spp., 10, 11f
- Dianthus callizonus*, anatomical variation of, 222
- Dicentrine, 92t, 97t, 117
antimicrobial activity of, 142
antiplasmodial activity of, 143
cytotoxicity of, 142
pharmacology of, 140
- Dicentrinone, 87t, 100t
cytotoxicity of, 144
pharmacology of, 143
- Diels-Alder cycloaddition
in erythroidine synthesis, 72
in lycoricidine synthesis, 25
in narciclasine synthesis, 27
in 8-oxo-erythroidine synthesis, 72
- 3,4-Dihydroanhydrolycorine, 9f
- Dihydrocaranine, 9f
- Dihydrolycorine, 9f
- Dihydrostauidine, 121
- 3,4-Dihydroxybenzaldehyde, 3, 4f
- Dihydroxycrinane, 12f
- 3,4-Dimethoxyphenethylamine, 64
- N,O*-Dimethylactinodaphnine. *See* Dehydrodiscretine
- 10,11-Dioxo-epierythratidine, 41, 41f
- 10,11-Dioxo-erysotramidine, antifeedant activity of, 42
- 10,11-Dioxo-erythratidinone, 41, 41f
- 10,11-Dioxo-erythratine, 41, 41f
- Discretamine, 94t
biological effects of, 107, 133
sources of, 87–88t, 92t, 124
- Discretine, 95t
antiplasmodial activity of, 133
sources of, 89t, 91t, 93t, 124
- Diterpenes, in *Duguetia* spp., 84
- DoInata ova population of *L. aestivum*, 177t
- Domino reactions, multicomponent, in *Erythrina* alkaloid synthesis, 65–66
- Dragabine, 116
- Drug development, knowledge-based, 157–158
- Duguecalyne, 97t
biogenesis of, 130
source of, 88t, 112
- Duguenaine, 97t, 105f
biogenesis of, 130
source of, 88t, 112
synthesis of, 119
- Duguespexine, 97t, 105f
source of, 90t, 112, 130
- Duguetia* alkaloids
biogenesis of, 122–131
biosynthesis of, 122–131
chemistry of, 117–122
chemosystematics of, 122–131
classification of, 86
list and synonyms of, 102–104t
molecular formulae of, 94–101t
pharmacology of, 132–146
sources of, 87–93t
structures of, 117–122
- Duguetia calycina*, alkaloids of, 88t, 108, 115
- Duguetia colombiana*, alkaloids of, 92t, 121

- Duguetia confinis*
 alkaloids of, 92–93t
 anatomical aspects of, 127
 in traditional medicine, 132
- Duguetia eximia*, alkaloids of, 91t, 114
- Duguetia flagellaris*, alkaloids of, 91–92t, 127–128
 in traditional medicine, 132
- Duguetia furfuracea*
 alkaloids of, 87t, 107, 119, 123, 128–130
 in traditional medicine, 132
- Duguetia gardneriana*, alkaloids of, 92t, 108
- Duguetia glabriuscula*, alkaloids of, 92t
 in traditional medicine, 132
- Duguetia hadrantha*, alkaloids of, 88t, 15, 129
- Duguetia magnolioidea*, alkaloids of, 92t, 108
- Duguetia obovata*, alkaloids of, 88–89t
- Duguetia odorata*, alkaloids of, 87–88t, 129, 130, 142
- Duguetia panamensis*, 121
- Duguetia spixiana*, alkaloids of, 89–91t, 115, 128
- Duguetia* spp.
 botanical classification of, 84–85
 cladistic analysis of, 85
 distribution of, 85–86, 127
 ethnopharmacology of, 132–133
Guatteria species', chemical similarity with, 130
 metabolic profiling of, 131
 secondary metabolites of, 84
- Duguetia staudtii*, alkaloids of, 93t
 anatomical aspects of, 122
 in traditional medicine, 132
- Duguetia stelechantha*, alkaloids of, 88t, 130
- Duguetia trunciflora*, alkaloids of, 92t, 108, 117
- Duguetia vallicola*, alkaloids of, 91t, 128
- Duguetine, 99t
 antiparasitic activity of, 142
 sources of, 87t, 92t, 117
- Duguevalline, 100t
 source of, 91t, 110, 114, 128
- Duguevanine, 97t
 sources of, 89t, 91t
- Duguexine, 99t
 sources of, 89–90t
- 2-Epi-erythritol, synthesis of, 59–61
- Erymelanthine, 67f, 77f
 synthesis of, 76–78
- Erysotramidine, synthesis of, 46–47
- Erysotrine,
 cytotoxicity of, 43
 synthesis of, 58, 59f
- Erythraline, biosynthesis of, 42f
- Erythartine N-oxide. *See* 11 β -Hydroxyerysotrine N-oxide
- Erythratidine, synthesis of, 56–57
- Erythravine
 anxiolytic activity of, 43
 synthesis of, 64–65
- Erythrina* alkaloids. *See also* Erythrinan ring formation
 anti-convulsive effects of, 44
 antifeedant activity of, 43
 anxiolytic activity of, 43
 aromatic D ring type, synthesis of, 44–66
 biosynthesis of, 41–42, 67
 curare-like activity of, 39, 43
 non-aromatic type, synthesis of, 66–78
 occurrence of, 40
 pharmacology of, 43–44
 sedative activity of, 44
 structures of, 39–40, 45f
 synthetic methods for, 44–78
 TRAIL interactions with, 44
- Erythrina latissima*, alkaloids of, 42
- Erythrina lysistemon*, alkaloids of, 40
- Erythrina mulungu*,
 alkaloids of, 42–43
 anxiolytic activity of, 43
- Erythrina velutina*, cytotoxicity of alkaloids of, 43
- Erythrinan ring formation
 asymmetric core approach in, 46
 of B ring, 47–50
 biphenyl framework in, 49
 of C ring, 50–55
 cyclization reactions for, 55–62
 3,4-Dimethoxyphenethylamine in, 64
 Grubb's ring-closing reaction in, 45, 62–65, 71, 72
 by metathesis, 62–65
 multiple ring closures in, 62–66
 Pictet-Spengler reaction in, 64
 of A ring, 45–47
 ruthenium catalyst in, 63
 strategies for, 45f

- Erythritol, 61
- Erythrocarine, synthesis of, 63–64
- β -Erythroidine, 67f
- synthesis of, 70–73
- Eschscholtzia California*, enzymes of, 124
- Essential oils, in *Duguetia* spp., 84
- Ethnopharmacology
- of *Duguetia* spp., 132–133
- of galanthamine, 168
- Eximine. *See* Dehydrodiscretine
- Eysotramidine, 47
- Fagus sylvatica*, shoot formation in, 206
- Ficus exasperata*, in traditional medicine, 132
- Flavonoids
- in *Duguetia* spp., 84
- in *Pancreatium* spp., 12
- Flexinine, synthesis of, 23f
- N-Formylaporphines, 111f
- N-Formylbuxifoline, 97t
- source of, 89t
- N-Formylduguevanine, 97t
- source of, 89t, 110–111
- N-Formylgalanthamine, 11f
- N-Formylnoraporphines, 97t, 105f
- N-Formylputerine, 97t
- source of, 88t, 111
- N-Formylxylopinine, 97t
- source of, 89t, 111
- Galanthamine, 3f, 11f, 159f
- absolute configuration of, 17f
- Alzheimer's disease treatment with, 20, 161t, 163–164
- content in *L. aestivum*, 176t, 179t, 180–182, 184t, 188t, 208f, 211t, 223–224f
- history of development, 158–160, 161t, 162
- ethnopharmacology of, 168
- NMR characteristics of, 17–18
- numbering of, 14t
- in *Pancreatium* spp., 10–11, 11f
- pharmacology of, 160, 161t, 162, 168
- sustainable production of, 162–163
- synthetic methods for, 20–23
- Galanthamine biosynthesis, 5f, 170–171.
- biomass growth stimulation in, 217–218
- clone specificity in, 250–252, 266
- disinfectant reliability in, 195–197
- dynamics of, 206–210, 213
- genotype features in, 171
- impact of light on, 227–228
- impact of music treatment on, 258–265
- inoculum significance in, 222–223, 225f
- in *L. aestivum*, 171–174, 176, 179–182, 185–187, 189
- plant propagation in, 189–191, 192t, 193–194
- stimulating factors in, 266
- tissue differentiation in, 197–199, 202–203, 266
- Galanthamine precursors, 244
- alkaloid production variability with, 254t
- clone specificity with, 250–252
- dry matter influenced by, 256f
- dynamics of alkaloid biosynthesis with, 248t
- feeding with, 244
- genotype interaction with, 245–247, 249, 255f
- lycorine stimulation with, 257f
- stimulation level of, 251
- Galanthane, 9f
- Galanthus* spp., distribution of, 159
- Geanthemum* spp., alkaloids of, 91t
- Glaziovine, 95t
- pharmacology of, 139
- source of, 91t, 109, 126
- Glycoerysodine, cytotoxicity of, 43
- Glycosidic chromones, 12
- 1-O- β -D-Glycosyllycorine, 9f
- β -D-gluc 4-O- β -D-Glycosyl narciclasine, 10f
- Govanine, 93t, 95t
- Guadiscine, 126
- Guatteria boliviana*, alkaloids of, 123
- Guatteria discolor*, alkaloids of, 114, 127, 128, 130
- Guatteria guianensis*, alkaloids of, 123
- Guatteria megulophylla*, alkaloids of, 123
- Guatteria melosma*, alkaloids of, 127
- Guatteria sagotiana*, alkaloids of, 112, 116, 128
- Guatteria* spp., alkaloid comparison with *Duguetia* spp., 130
- Guatterine, 93t, 98t
- Habranthine, 11f
- Hadrantha* spp., alkaloids of, 88t

- Hadranthine A, 88t, 101t
 antiplasmodial activity of, 146
- Hadranthine B, 88t, 101t
 cytotoxicity of, 145
- Haemanthamine, 3f, 13f
 absolute configuration of, 18f
 antiplasmodial activity of, 33
 NMR characteristics of, 18
 in *Pancratium* spp., 12, 13f
 synthetic methods for, 23–24, 29–30f
 as tazettine precursor, 4, 6f
- Haemanthidine, 6f, 13f
 antiplasmodial activity of, 33
 as tazettine precursor, 4, 6f
- Heck reaction, erythrinan ring formation with, 60
- Hippadine, 9f
- Hippeastrine, 8f
 apoptosis induction by, 31t
 cytotoxicity of, 31t
- Hofmannase, 128–129
- Holographic memory, of genes, 265
- Homoerythrina skeleton, 40f
 synthesis of, 65–66
- Homomoschatoline. *See* O-Methylmoschatoline
- 7-Hydroxyaporphines, 98–99t, 105f, 113f
 isolation of, 112–113
- ent*-6-Hydroxybufanisine, 13f
- 11 β -Hydroxyerysotramidine, 40, 41f
- 11 β -Hydroxyerysotrine, 40, 41f, 43
 anxiolytic activity of, 43
- 11 β -Hydroxyerysotrine *N*-oxide, 40, 41f
- 3-Hydroxynornuciferine, 96t
 source of, 90t, 128
- Hydroxyvittatine
 apoptosis induction by, 31t
 cytotoxic activity of, 31t
- 11-Hydroxyvittatine, 13f
- Hymenocallis* spp., 6
- Imbiline-1, 101t
 antiplasmodial activity of, 146
 cytotoxicity of, 145
 source of, 88t
 synthesis of, 119
- Imine, 68
- In vitro* culture systems. *See also*
 Galanthamine biosynthesis;
Leucojum aestivum
L. aestivum clone codes in, 177–178t
 alkaloid production in, 30
- Indigenous groups, wealth flow to, 164
- Insecticidal activity, of cocculolidine, 68
- Intramolecular cycloaddition, *Iodoalkene*, formation of, 71
- Isoboldine, 96t
 pharmacology of, 140
 source of, 91t
- Isochondodendrine, 87t, 94t, 107, 123
 NMR studies of, 117
 pharmacology of, 133
- Isocorydine, 87t, 91t, 97t, 126
- Isocorypalmine, 92–94t
- Isohellibiline, 67f
- Isolaureline, 88t, 96t
 antiplasmodial activity of, 143
- Isopiline, 96t
 pharmacology of, 141
 source of, 91t
- Isoquinoline alkaloids, from *Duguetia* spp., 84
- Jasmonic acid
 elicitation of alkaloid biosynthesis by, 236, 237t, 238–240, 241t, 242–244
L. aestivum biological clock, effect on, 235
 secondary metabolism enhancement by, 236
- Jatrorrhizine, 95t
 pharmacology of, 137–139
 sources of, 92t, 108, 124
- Kalinata population of *L. aestivum*, 175f, 176–177t, 193f
- Karaagach population, of
L. aestivum, 175f
- Kinetin, *L. aestivum* cultures, effects on, 234
- Kirlian photography, 258
- L. aestivum* *See* *Leucojum aestivum*
- Lanuginosine, 87t, 90t, 92t, 100t
- Lauroscholtzine. *See*
N-Methylaurotetanine
- Leucojum aestivum* (*L. aestivum*)
 air refreshment for, 226
 alkaloid location in, 197–199, 200–201t, 202–203
 alkaloid profile alterations in, 214, 216–217
 biological clock in, 203–204, 235

- biomass growth stimulation in, 217–218
- bulblet formation dynamics of, 204–206
- cultivation conditions for, 218–219
- culture medium composition for, 229–235, 235f
- disinfection of, 195–197
- dormancy break in, 206
- fluctuations in, 209f
- galanthamine content of, 176t, 179t, 180–182, 184t, 188t, 208f, 211t, 223–224f
- galanthamine precursors added to, 244–258
- genotype influence on, 207, 208f, 245–247, 249
- heterogeneity of, 172, 175f
- historical galanthamine production from, 168
- illumination regime for, 226
- inoculum significance in, 222–223, 225f
- leaf to bulblet ratio of, 221f
- light influence on, 227–228
- liquid cultures of, 219–226, 221f, 223–224f
- lycorine in, 179t, 180–181f, 187, 211t
- music influence on, 259f
- propagation coefficients of, 192t, 193f, 205f
- propagation of, 189–191, 193–194
- seasonal variations of, 209
- shoot formation of, 204, 205f
- in situ* screening of, 183t
- temperature influence on, 226f
- temporary immersion systems for, 222
- in vitro* clone codes of, 177–178t
- in vitro* culture of, 30
- Liquid cultures, of *L. aestivum*, 219–226
 - agar-solidified medium for culture of, 220
 - galanthamine content with, 223–224f
 - leaf to bulblet ratio with, 221f
- Liridine. *See* O-Methylmoschatoline
- Liriodenine, 99t
 - antifungal activity of, 144
 - antileishmania activity of, 144
 - cytotoxicity of, 143
 - metal complexes of, 130
 - sources of, 87t, 93t
- Lozenski pat population of *L. aestivum*, 178t
- Luteanine *See* Isocorydine
- Lycoramine, 11f
 - Birch-Cope sequence in synthesis of, 21f
- Lycorenine, 3f
 - absolute configuration of, 14f
 - apoptosis induction by, 31t
 - biosynthesis of, 5f
 - cytotoxicity of, 31t
 - NMR characteristics of, 14
 - numbering of, 14t
 - in *Pancratium* spp., 8f
- Lycoricidine, synthetic methods for, 25, 26f
- Lycorine, 3f
 - absolute configuration of, 15f
 - antiplasmodial activity of, 33
 - apoptosis induction by, 31t
 - biosynthesis of, 5f, 9f
 - cytotoxicity of, 31t, 32
 - in *L. aestivum*, 179t, 180–181f, 187, 211t
 - music impact on production of, 263
 - NMR characteristics of, 15
 - numbering of, 14t
 - in *Pancratium* spp., 9f
 - precursors stimulation on structure of, 3f
 - synthetic methods for, 19–20
- Lysicamine, 90t, 99t
 - antileishmania activity of, 144
 - cytotoxicity of, 144
- Macowine, 12f
- Maize, erythrinan alkaloid protection of, 43
- Malmea depressa*, 123
- Malmea gaumeri*, 123
- Maritidine, 13f
 - synthesis of, 24, 24f
- MDR gene, pretazettine effect on, 32
- Meiogyne virgata*, alkaloids of, 116
- Metabolic profiling, of *Duguetia* spp., 131
- Metathesis, multiple erythrinan ring formation by, 62–65
- 7-Methoxyaporphines, 99t
- Methoxyatherosperminine, 90t, 100t, 115
- 11 β -Methoxyerysotramidine, 40
- 11 β -Methoxy-10-oxoerysotramidine, antifeedant activity of, 42
- 7-Methoxy-4-hydroxyaporphines, 99t

- 3-Methoxysampangine, 88t, 101t
antifungal activity of, 146
antimycobacterial activity of, 146
antiplasmodial activity of, 146
N-Methylasimilobine, 95t
pharmacology of, 141
source of, 89t
N-Methylbuxifoline, 89t
N-Methylcalycinine, 89t, 97t
O-Methylerysodienone, synthesis of, 49–50
N-Methylglaucine, 87t, 96t, 129
N-Methylguatterine, 87t, 98t, 129, 142
6-*O*-Methylhaemanthidine, 13f
O-Methylisopiline, 90t, 91t, 96t
N-Methylaurelliptine. *See* Isoboldine
N-Methylaurotetanine, 96t
pharmacology of, 141
source of, 91t
O-Methylmoschatoline, 88t, 90–92t, 91t, 99t
4'-*O*-Methylnorbelladine
biosynthesis of, 4f
biosynthetic coupling of, 4
phenol oxidative coupling of, 5f, 6f
O-Methylnorlirinine.
See *O*-Methylisopiline
N-Methylpachypodanthine, 93t, 99t, 113
O-Methylpukateine, 88t, 96t
N-Methyltetrahydropalmatine, 95t
sources of, 87t, 124
Methylthio amides, cyclization of, 52
N-Methylxylopine. *See* Isolaureline
Micheline B. *See* Liriodenine
Monoterpenes, in *Duguetia* spp., 84
Montanine, 3f, 10f
anti-inflammatory activity of, 33
antimicrobial activity of, 33
antioxidant activity of, 33
biosynthesis of, 6
NMR characteristics of, 15–16
numbering of, 14t
in *Pancreaticum* spp., 9–10, 10f
synthetic methods for, 27–28, 29f
Morphinandienones, 105f, 109f
chemistry of, 117
molecular formula of, 95t
synthesis of, 118f
stereochemistry of, 126
Multiple myeloma cells, lycorine
impact on, 32
Music
alkaloid biosynthesis influenced by, 260f, 263–265
bad-language variant of, 264
in galanthamine synthesis, 258–265
genotype *vs.*, 261–262t
L. aestivum, influence on, 259f
metabolic modulation by, 258
water memory and, 258
Narciclasine, 3f, 10f
absolute configuration of, 16f
antitumor activity of, 33
apoptosis induction by, 31t
biosynthesis of, 6
cytotoxic activity of, 31t
NMR characteristics of, 16
numbering of, 14t
in *Pancreaticum* spp., 9–10, 10f
synthetic methods for, 25–27
Narcissus confusus, *in vitro* culture of, 30
Narcissus pseudonarcissus, lycorine in, 2
Nickel, in erythrinan ring formation, 50, 62
Nickel-mediated alkylative
carboxylation reactions, 62
8-Nitroisocorydine, 87t, 97t, 112, 117
formation of, 119
spectral properties of, 119
N-Nitrosoanonnaine, 87t, 97t, 112, 117
N-Nitrosoaporphines, 112f, 117
N-Nitrosonoraporphines, 97t, 105f, 117
N-Nitrosoxylopine, 87t, 97t, 112, 117
NMR. *See* Nuclear magnetic resonance
Noramurine, 42f
Noratherosperminine, 88t, 100t, 115, 131
biogenesis of, 128
Norbelladine, biosynthesis of, 3, 4f
Nordragabine, 115
N-Norgalanthamine, 11f, 214
Norglaucine, 92t
Norisocorydine, 87t, 97t, 126
biosynthesis of, 141
pharmacology of, 140
Norisosalutaridine, 42f
N-Norlycoramine, 11f
10-Norneronine, 8f
Nornuciferidine, 90t, 96t, 98t
Nornuciferine, 90t, 128
antileishmania activity of, 142
pharmacology of, 140
Noroliveridine, 89–90t, 90t, 98t
Norpachyconfine, 89t, 98t

- Norpachystaudine, 99t
 configuration of, 127
 source of, 93t, 113
- Norpluviine
 apoptosis induction by, 31t
 biosynthesis of, 9f
 cytotoxicity of, 31t
 in lycorenine biosynthesis, 5f
- 9-Norpluviine, 9f
- Norreticuline, in erythraline
 biosynthesis, 42
- Nuclear magnetic resonance
 (NMR) studies
 of *Amaryllidaceae* alkaloids, 14–15
 of crinine-type alkaloids, 18
 of galanthamine-type alkaloids, 17–18
 of haemanthamine-type alkaloids, 18
 of lycorenine-type alkaloids, 14
 of lycorine-type alkaloids, 15
 of montanine-type alkaloids, 15–16
 of narciclasine-type alkaloids, 16
 of staudine, 121
 of tazettine-type alkaloids, 16–17
- Obovanine, 87–88t, 96t
- Oliveridine, 89–92t, 98t, 130
- Oliveroline, 87t, 91t, 93t, 98t
 cytotoxicity of, 142
- Opium poppy, alkaloid biosynthesis
 in, 124
- Ormana population of *L. aestivum*, 175f,
 176–177t, 193f
- Oxidative coupling
 of 4'-*O*-methylnorbelladine, 5f
- Oxoaporphines, 99–100t, 106f, 113f, 114
 pharmacology of, 143–144
- Oxobuxifoline, 89t, 92t, 100t
- 8-Oxoerymelanthine, 67f, 77f
 synthesis of, 76–78
- 8-Oxo-erythraline, cytotoxicity of, 43
- 8-Oxo-erythrinan skeleton, 40f
- 8-Oxo- β -erythroidine, 67f
 synthesis of, 70–73
- Oxo-isocalycine, 114, 128
- Oxonuciferine. *See* Lysicamine
- Oxopukateine, 88t, 91t, 100t
- Oxoputerine, 88t, 91t, 100t
- Oxoushinsunine. *See* Liriodenine
- Oxxylopine. *See* Lanuginosine
- N*-Oxyatherosperminine, 90t, 100t, 130
- N*-Oxycodamine, 89t, 94t, 123
- N*-Oxyduguetine, 87t, 99t
- N*-Oxyduguexine, 89t, 99t
- N*-Oxyguatterine, 93t, 98t
- N*-Oxyoliveridine, 89–90t, 90t, 98t
- N*-Oxyoliveroline, 92t, 98t
- N*-Oxypachyconfine, 89t, 98t
- N*-Oxyspixianine, 89t, 99t
- Pachyconfine, 89t, 93t, 98t
- Pachypodanthine, 91t, 93t, 99t, 113
- Pachystaudine, 99t
 antiviral activity of, 142
 configuration of, 127
 source of, 93t, 113
- Pancracine, 10f
 absolute configuration of, 15f
 antiplasmodial activity of, 33
 in *Pancreatium* spp., 9–10
- Pancrassidine, 9f
- Pancrastatin, 10f
 apoptosis induction by, 32
 synthetic methods for, 25–27, 26f
- Pancratinine A, 8f
- Pancratinine B, 10f
 in *Pancreatium* spp., 10
- Pancratinine C, 10f
- Pancratinine D, 9f
- Pancratistatin, 10
- Pancreatium* alkaloids, 1
 anticancer activity of, 31–33, 31t
 antiplasmodial activity of, 33
 apoptosis induced by, 31t, 32
 biological activity of, 31–33
 crinine-type, 12
 cytotoxic activity of, 31t
 galanthamine-type, 10–11, 11f
 haemanthamine-type, 12, 13f
 lycorenine-type, 8f
 lycorine-type, 9f
 montanine-type, 9–10, 10f
 narciclasine-type, 9–10, 10f
 phytochemical research on, 34
 synthesis of, 18–30
 tazettine-type, 9–10, 11f
 as zwitterionic compounds, 8f
- Pancreatium arabicum*, 7t
- Pancreatium biflorum*, 7t
- Pancreatium canariense*, 8f
 distribution of, 7t
 montanine-type alkaloids in, 10
 narciclasine-type alkaloids in, 10
- Pancreatium centrale*, 7t
- Pancreatium donaldi*, 7t

- Pancratium foetidum*, 7t
Pancratium illyricum, 7t
Pancratium landesii, 7t
Pancratium longiflorum, 7t
Pancratium maritimum, 8f
 distribution of, 7t
 montanine-type alkaloids in, 10
 tazettine-type alkaloids in, 9–10, 11f
 in vitro culture of, 30
Pancratium maximum, 7t
Pancratium parvicoronatum, 7t
Pancratium parvum, 7t
Pancratium sickenbergeri
 distribution of, 7t
 montanine-type alkaloids in, 10
Pancratium spp.
 Amaryllidaceae alkaloids in,
 7–12, 14t
 botanical description of, 7
 distribution of, 6, 7t
 secondary metabolites of, 12, 13f
 species list, 7t
Pancratium st.-mariae, 7t
Pancratium tenuifolium, 7t
Pancratium tortuosum, 7t
Pancratium trianthum, 7t
Pancratium triflorum, 7t
Pancratium verecundum, 7t
Pancratium zeylanicum, 7t
 Petkaki population of *L. aestivum*,
 175f, 176–177t, 193f
 Pharmacology
 of aminoethylphenanthrenes, 144–145
 of anonaine, 139, 141
 of aporphines, 139–143
 of atherospermidine, 143
 of atherosperminine, 144–145
 of azaanthraquinone, 146
 of benzyltetrahydroisoquinolines,
 133–134
 of berbines, 134–137
 of bisbenzylisoquinolines, 134
 of copyrine alkaloids, 145–146
 of *Duguetia* alkaloids, 132–146
 of *Erythrina* alkaloids, 43–44
 of galanthamine, 160, 161t, 162, 168
 of glaziovine, 139
 of isoboldine, 140
 of isopiline, 141
 of jatrorrhizine, 137–139
 of liriodenine, 143–144
 of *N*-methylassimilobine, 141
 of *N*-methyllaurotetanine, 141
 of oxoaporphines, 143–144
 of protoberberines, 137–139
 of reticuline, 133
 of sampangine, 145–146
 of tetrahydropalmatine, 134–137
 of xylopine, 139–140
 Phellibiline, 67f
 Phenolic acids, in *Pancratium* spp., 12
 Phenol oxidative coupling, in
 Amaryllidaceae alkaloid
 biosynthesis, 4, 5f
 Phenylthioerythrinan, 58
 Pictet-Spengler reaction
 in erythrinan ring formation, 64
 in selaginoidine synthesis, 74–75
 Plant growth regulators, effect on
 L. aestivum cultures, 234
 Polyalthine, 92t, 99t
Polyantha spp., alkaloids isolated
 from, 91t
Populus tremula, shoot formation
 in, 206
 Pretazettine, 6f, 11f
 MDR-reversing activity of, 32
 in *Pancratium* spp., 10
 Proaporphine, 95t, 105t, 109f
 distribution of, 109
Proiphys spp., 6
 Proteody, in protein synthesis, 265
 Protoberberines, 95t, 101t, 105f
 isolation of, 108–109
 pharmacology of, 137–139
 Protoberberine-styrene adduct, 116f
 Pseudolycorine, 9f
 Pseudopalmatine, 95t
 sources of, 87t, 91t, 108, 142
 Psilopine. *See* Atherospermidine
 Pummerer reaction, in *Erythrina* alkaloid
 synthesis, 57–58
 Puterine, 88t, 96t

 Radio waves, DNA produced, effect of
 metabolism, 265
 Reductive amination, in erythroidine
 synthesis, 71
 (S)-Reticuline, 94t
 in benzylisoquinoline
 biosynthesis, 123
 pharmacology of, 133
 sources of, 87t, 92t, 117
 Rice test, 260

- Roemerolidine, 90t, 98t
Rogersine. *See* N-Methylaurotetanine
Rurrebanidine, 90t, 98t
Rurrebanine, 90t, 98t
- Salt composition, effect on *L. aestivum* culture, 230–233
- Sampangine, 101t
antifungal activity of, 146
antimycobacterial activity of, 146
antiplasmodial activity of, 146
cytotoxicity of, 145
source of, 88t
- Scoulerine, biosynthesis of, 124
(9S)-Sebiferine, 95t
source of, 89t, 117
stereochemistry of, 126
- Sedation, with *Erythrina* alkaloids, 44
- Selaginoidine, 67f, 74
synthesis of, 74–75
- Spermatheridine. *See* Liriodenine
Sphaerantha spp., alkaloids of, 88t
- Spiduxine, 95t
biogenesis of, 125f
source of, 90t, 108
- Spiguetidine, 90t, 101t, 116, 130
Spiguetine, 91t, 101t
- Spirocyclization, in erythrinan ring formation, 50
- Spixianine, 89t, 99t
- Staudine, 101t
chemistry of, 121
isolation of, 120
NMR spectrum of, 121
source of, 93t, 116
- Stephania rotunda*, 133
- Strecker reaction, erythrinan core formation with, 61
- Sucrose, effect on *L. aestivum* culture, 229–230
- Suzuki-Miyaura coupling reaction, 19
- Synthetic methods for
augustine, 23f
brunsvigine, 29f
cocculolidine, 67–70
crinine, 23–24, 25f
3-demethoxyerythratidinone, 51f, 52–54, 55f
dihydrodiscretine, 50
duguenaine, 119
erymelanthine, 76–78
erysotramidine, 46–47
erysotrine, 58, 59f
erythratidine, 56–57
erythravine, 64–65
Erythrina alkaloids, 44–78
 β -erythroidine, 70–73
galanthamine, 20–23, 258–265
haemanthamine, 23–24, 29–30f
homoerythrina skeleton, 65–66
imbiline-1, 119
lycoricidine, 25, 26f
lycorine, 19–20
maritidine, 24, 24f
O-methylerysodienone, 49–50
montanine, 27–28, 29f
narciclasine, 25–27
non-aromatic *Erythrina* alkaloids, 66–78
8-oxo-erymelanthine, 76–78
8-oxo-erythroidine, 70–73
pancrastatin, 25–27, 26f
Pancratium alkaloids, 18–30
selaginoidine, 74–75
tazettine, 23–24, 30f
- Tazettine, 3f, 11f
absolute configuration of, 16f
apoptosis induction by, 31t
biosynthesis of, 4, 6f
cytotoxicity of, 31t
NMR characteristics of, 16–17
numbering of, 14t
in *Panocratium* spp., 9–10, 11f
synthetic methods for, 23–24, 30f
- Tetrahydrocolumbamine, biosynthesis of, 124
- Tetrahydrojatrorrhizine. *See* Corypalmine
- Tetrahydroplamatrubine, 124
- Tetrahydropalmatine, 94t
pharmacology of, 134–137
sources of, 91t, 92t
- Tetrahydroprotoberberine oxidase, 124
- Thaicanine, 95t
antiplasmodial activity of, 137
source of, 92t, 108
- Thalictrum minus*, 244
- TRAIL. *See* Tumor necrosis factor-related apoptosis-inducing ligand
- Trichoguatine, 130

- 2,4,5-Tromethoxystyrene,
 formation from staudine, 121
 occurrence, 121
- Trimethylaluminum, domino reactions
 mediated with, 65–66
- Triterpenes, in *Duguetia* spp., 84
- Tumor necrosis factor-related
 apoptosis-inducing ligand
 (TRAIL), 44
- Ungeremine, 9f
 antiplasmodial activity of, 33
 apoptosis induction by, 31t
 cytotoxicity of, 31t
- Ungiminorine, 214
- Ungiminorine *N*-oxide, 9f
- Vagaria* spp., 6
- Vessellie population of *L. aestivum*, 175f,
 176–177t, 193f
- Vittatine, 13f
- Water memory, 258
- Xylopinine, 96t
 antileishmania activity of, 142
 antimicrobial activity of, 142
 antiplasmodial activity of, 143
 pharmacology of, 139–140
 sources of, 87–88t
- Xylopinine, 95t
 sources of, 89t, 91t
- Zefbetaine, 9f
- Zwitterionic compounds, *Pancratium*
 alkaloids as, 8f

SUBJECT INDEX

- 14-*O*-Acetaldelectinine, 528t
 16 β -Acetoxycardiopetaline (A1a-4), 19t, 329t
 6-Acetoxy-containing alkaloids, fragmentation ions, 444
 Acetoxy groups
 chemical shifts, 383t, 418t
 elimination reactions, 464–466
 selective hydrolysis, 481–482
 3-Acetylaconifine (A1c-46), 127–128t, 386t
 3-Acetylaconitine (A1c-30 / flaconitine), 118–120t, 251t, 337t, 339t, 391t, 522t
 14-*O*-Acetyl-10,12-anhydrocytoscarpine, fragmentation ions, 444
 8-Acetyl-14-anisoyltalatisamine, 336t
N-Acetylanthranoyl groups
 carbon-13 chemical shifts, 415t–418t
 proton chemical shift ranges, 383t
 Acetylated derivatives, taxoid synthesis, 511–514
 14-Acetylbearline (B1d-37), 221t, 340t, 544t
 3-*O*-Acetylbeiwutine (A1c-44), 126–127t, 340t
 8-Acetyl-14-benzoylchasmanine (A1b-74 / crassicaudine), 82–83t, 336t
 Acetylbenzoyltalatisamine,
 α -fragmentation, 443
 14-*O*-Acetylbikhaconine, 524t
 14-Acetylbrownine (B1a-44), 167–168t, 333t, 524t, 545t
 18-Acetylcammaconine (A1a-7), 20–22t, 331t
 15-*O*-Acetylcardiopetamine, 525t
 14-Acetylchasmanine (A1b-57), 77t, 333t
 8-Acetylcondelphine (A1a-48), 36–37t, 333t
 15-Acetyl-13-dehydrocardiopetamine (A1c-10), 112t, 339t
 1-*O*-Acetyldelecosine, 528t
 14-Acetyldelecosine (B1a-21 / delecosine 14-*O*-acetate), 154–155t, 333t
O-Acetyldelectine (B1d-5 / anderssonidine), 207–208t, 337t, 528t, 544t
N-Acetyldelectine (B1d-11 / 14-deacetylajadine), 209–210t, 337t, 523t, 528t, 544t
 6-Acetyldepheline (B1c-26), 193t, 333t
 1-Acetyldephisine (A1b-49), 75t, 335t
 6-*O*-Acetyldemethylenedelcorine (B1a-42 / leucostine A), 166t, 333t
 14-Acetyldihydrogadesine (B1a-14), 151t, 332t
 8-*O*-Acetylfalconerine (A1b-122), 102t, 339t
N-Acetylflavaconitine (A1V-8), 143–144t, 338t
 14-Acetylgadesine (B1I-9), 236–237t, 331t
 14-Acetylgenicunine B (A1a-53), 39–40t, 331t
 6-Acetylheteratisine (D-6), 256t, 330t, 533t, 546t
 8-Acetylheterophyllisine, 458t
 8-Acetylheterophyllisine (D-3), 255t, 330t, 533t
 14-*O*-Acetyl-10-hydroxyneoline (A1b-58), 78t, 333t
 8-*O*-Acetyl-15 α -hydroxyneoline (taurenine), 106–107t, 333t
 1-*O*-Acetylkarakoline, 534t, 546t
 14-*O*-Acetylkarakoline (A1a-45), 35–36t, 330t, 534t, 544t
 8-*O*-Acetylkarasamine (A1a-50), 38t, 330t
 Acetyllycotoconine, *N*-oxidations, 473, 474f
 3-Acetylmesaconitine *see* tuberanine
 6-*O*-Acetyl-14-*O*-methyldephinifoline (B1a-20), 154t, 333t
 14-*O*-Acetyl-8-*O*-methyl-18-*O*-2-(2-methyl-4-oxo-4*H*-quinazoline-3-yl)-benzoylcammaconine (A1a-102), 54t, 339t
 14-Acetylneoline (bullatine C), 71–72t, 332t, 539t
 14-Acetylnudicaulidine (B1a-43), 167t, 332t
 14-*O*-Acetylperegrine (A1b-56), 77t, 333t
 3-Acetylpsedaconine
 imination reactions, 470, 471f
 oxidation reactions, 477
 14-Acetylsachaconitine (austrosonitine A), 330t
 14-*O*-Acetylsenbusine A (A1b-38), 71t, 332t
N-Acetylsepaconitine, 540–541t, 547t
 7-*O*-Acetylseptontrionine, fragmentation ions, 444, 445f

- 14-*O*-Acetyltakaosamine (BIa-23), 155–156t, 332t
- 14-Acetylaltatisamine, iminations, 472, 474f
- 14-Acetylaltatizamine (AIIa-51 / 14-acetylaltatisamine), 38–39t, 332t, 541t, 548t
- 14-Acetylvirescenine (BIa-7), 147–148t, 332t, 543t
- 3-Acetylyunaconitine, rearrangements, 484–485, 487f
- 3-Acetylyunaconitine, oxidations, 472, 473f
- Acobretine A (AIIa-88), 50t, 335t
- Acobretine B (AIIa-95), 52t, 335t
- Acobretine C (AIIa-96), 52t, 336t
- Acobretine D (AIIa-92), 51t, 337t
- Acobretine E (AIIa-90), 50t, 334t
- Acofamine A (AIIc-16), 114t, 336t
- Acofamine B (AIIc-18), 114t, 336t
- Acoforesticine (AIIb-97), 92–93t, 335t
- Acoforestine (AIIb-98), 92–93t, 337t, 457t
- Acoforestinine (AIIb-115 / 8-*O*-ethyllyunaconitine), 100–101t, 338t, 543t
- Acoforine (AIIa-52), 39–40t, 333t
- Acoleareine (AIIb-43), 73t, 334t
- Acomonine *see* delsoline
- Aconasutine (CI-1), 250t, 329t
- Aconifine (AIIc-45 / 10 β -hydroxyaconitine), 126–127t, 339t, 521t
- Aconine (AIIc-19), 115t, 333t, 521t, 544t
- Aconitella stenocarpa*, 302t
- Aconitilearine (AIIi-11), 137–138t, 332t, 386t
- Aconitine (AIIc-29), 338t, 385–386t, 457t, 521–522t, 544t
- acylation reactions, 478
- occurrence, 118–122t
- stability in solvents, 483–484
- Aconitine-type alkaloids (A), 18–144t, 451–453, 457–458t
- amide-subtypes, 142–144t
- amine-subtypes, 18–141t
- biosynthesis, 362, 362–371, 363f, 364, 364f
- chemical shifts, 395t, 401–406t, 419–428t
- code numbers, 343–362
- α -fragmentation, 439, 440f
- imine-subtypes, 138–141t
- lipo-alkaloids, 129–135t
- N,O*-mixed acetal-subtype, 135–138t
- nonoxygenation at C-6, 18–54t
- oxygenation at C-6 and C-15, 106–128t
- oxygenation at C-6/nonoxygenation at C-15, 55–106t
- Aconitum* spp. 266–302t, 374–380
- A. albobolaceum*, 266t
- A. altaicum*, 266t
- A. anglicum*, 266t
- A. angustifolium*, 266t
- A. anthora*, 266t
- A. anthoroideum*, 266t
- A. arcuatum*, 266t
- A. austroyunnanense*, 266t
- A. baicalense*, 267t
- A. balfourii*, 267t
- A. barbatum*, 267–268t
- A. brachypodium*, 268t
- A. brevicaratum*, 268t
- A. bullatifolium*, 268t
- A. bulleyanum*, 268t
- A. callianthum*, 269t
- A. cammarum*, 269t
- A. carmichaeli*, 269–270t, 543t
- A. chasmanthum*, 270t
- A. chinense*, 270t
- A. cochleare*, 271t
- A. columbianum*, 271t
- A. confertiflorum*, 271t
- A. contortum*, 271t
- A. coreanum*, 271t
- A. crassicaule*, 271–272t
- A. czeakanovskiyi*, 272t
- A. deinorrhizum*, 272t
- A. delavayi*, 272t
- A. delphinifolium*, 272t
- A. dolichorhynchum*, 272t
- A. duclouxii*, 273t
- A. dunhuaense*, 273t
- A. episcopale*, 273t
- A. excelsum*, 273t, 284–285t
- A. falconeri*, 273–274t
- A. fauriei*, 274t
- A. ferox*, 274t
- A. finetianum*, 274t
- A. firmum*, 275t
- A. fischeri*, 275t, 282t
- A. flavum*, 275t
- A. forrestii*, 275–276t
- albovillosum*, 276t
- A. franchetii*, 276t
- A. fukutomei*, 276t
- A. geniculatum*, 276–277t
- A. gigas*, 277t
- A. grossedentatum*, 277t
- A. gymnantrum*, 277t
- A. habaense*, 278t
- A. hakusanense*, 278t

- A. hemsleyanum*, 278–280t
A. heterophyllum, 280t
A. ibukiense, 280–281t
A. jaluense, 281t
A. japonicum, 281–282t
A. jinyangense, 282t
A. kamtschaticum, 282t
A. karakolicum, 282–283t
A. kongboense, 283t
A. kusnezoffii, 283–284t
A. laeve, 284t
A. lamarckii, 284t
A. leucostomum, 273t, 284–285t
A. liangshanicum, 285t
A. liaotungense, 285t
A. liljestrandii, 285t
A. longtouense, 286t
A. lycototum, 286t
A. macrorhynchum, 286t
A. manshuricum, 286t, 287t
A. mazimai (*A. yezoense*), 286t
A. mitakense, 286–287t
A. miyabei, 287t
A. mokchangense, 287t
A. monticola, 287t
A. nagarum, 287t
A. napellus, 288–289t, 548t
A. napiforme, 289t
A. nasutum, 289t
A. nemorum, 290t
A. nevadense, 290t
A. orientale, 290t
A. orochryseum, 290t
A. ouvardianum, 290t
A. palmatum, 290t
A. paniculatum, 290t
A. pendulum, 290t
A. pengzhouense, 292t
A. piepunense, 291t
A. polyschistum, 291t
A. pseudogeniculatum, 291t
A. pseudolaeve, 291t
A. pseudostaphianum, 291t
A. pulchellum, 292t
A. racemosum, 292t
A. raddeanum, 292t
A. rubricundum, 292t
A. sachalinense, 292t
A. sajanense, 292t
A. sanyoense, 292–293t
A. saposhnikovii, 293t
A. scaposum, 293t
A. senanense, 293t
A. septentrionale, 293t
A. sinomontanum, 293–294t
A. sinonapelloides, 294t
A. soongaricum, 294t
A. spicatum, 294t
A. stapfianum, 294t
A. stoerckianum, 294t
A. subculatum, 294t
A. subcuneatum, 294–295t
A. sungpanense, 295–296t
A. szechenyianum, 296t
A. taipeicum, 296t
A. talassicum, 296t
A. tanguticum, 296t
A. tasiromontanum, 296t
A. tatsienense, 296–297t
A. tauricum, 297t
A. tortuosum, 297t
A. toxicum, 297t
A. transsectum, 297–298t
A. tranzschelii, 298t
A. tschangbaischanese, 298t
A. tuberosum, 298t
A. tuguancunense, 298t
A. turczaninowii, 298t
A. uchiyamae, 298t
A. umbrosum, 298t
A. variegatum, 298–299t
A. vilmorinianum, 299–300t
A. violaceum, 300t
A. vulparia, 300t, 548t
A. yesoense, 300–301t
A. zeravschanicum, 301t
A. zuccarini, 301t
 aminoalcohol functionalizations, 370, 371f
 characteristic alkaloids, 379–380
 chemotaxonomy, 374–380
 natural occurrences, 266–302t
 Aconorine (A1a-91), 51t, 335t
 Acorientine, 523t
 Acosanine (B1a-33 / 6-demethyldephatine), 161–162t, 332t
 Acoseptine (F-1), 263t, 335t, 392t
 biosynthesis, 374, 374f
 Acoseptridine (BIII-9), 242t, 335t
 Acoseptridinine (A1a-87), 49t, 333t
 Acoseptrigine (A1b-46), 74t, 333t
 Acoseptrine (B1d-2), 206–207t, 335t
 Aconine *see* beiwudine
 Acotoxinine (A1b-131), 105–106t, 336t
 Acovulparine (BIII-4), 241t, 330t, 390t
 Actaline, biosynthesis, 364, 364f

- Acylation reactions, 478–481
 Ajacine (BIId-16), 213–214t, 337t, 523t, 544t
 Ajaconine, 523t
 lycoctonine biosynthesis, 368f, 369–370
 Ajacusine (BIId-33), 219–220t, 341t
 Ajadelphine (BIb-1), 178t, 332t
 Ajadelphinine (BIc-1), 185–186t, 330t, 388t, 523t
 Ajadine (BIId-13), 212t, 338t, 523t
 Ajadinine (BIId-11), 243t, 337t
 Ajanine (BIId-15), 212t, 340t
 Alboviolaconitine A (BIa-41), 166t, 333t
 Alboviolaconitine B (BIId-23), 215–216t, 339t
 Alboviolaconitine C (BIId-22), 215–216t, 339t
 Alboviolaconitine D (BIId-10), 243t, 338t
 Alcohol oxidations, 475–478, 479f
 Aldehyde synthesis, 475–477
 Aldohypaconitine (AIV-7), 143–144t, 337t
 Aldol condensations, C₂₀/C₁₉ alkaloid biogenesis, 368f
 Aljesaconitine A (AIIc-26), 117t, 338t, 524t
 Aljesaconitine B (AIIc-25), 117t, 339t
 Alkaloid A (AIIb-40 / dicoloridine), 72–73t
 Alkaloid B (AIIb-3), 55t, 329t
 Alpinine (BIId-43), 226t, 341t
 Altaconitine, 457t, 461f
 Altaconitine (AIIc-49), 128t, 339t, 386t, 524t
 Ambiguine (BIb-20), 184t, 334t
 Amide-subtypes, aconitine-type (AIV), 10f, 142–144t
 Amide-subtypes, lycoctonine-type (BIV), 245–249t
 Aminations, 470–475
 C₂₀/C₁₉ alkaloid biogenesis, 366f
 Amine-subtypes, aconitine-type alkaloids (AI), 8–12, 18–144t
 Amine-subtypes, lycoctonine-type (BI), 13–14, 145–249t
 Aminoalcohol alkaloids, functionalizations, 370, 371f
 Amino alcohol groups, antiarrhythmic effects, 516–517
 Amino substitutions, hydroxyl groups, at C-8, 411, 414t
 Analgesic activity, 515–516
 Andersonidine *see* O-acetyldelectine
 Andersonine (BIId-52), 229–230t, 341t
 Anhweidelphinine (BIId-15), 244–245t, 338t, 544t
 10,12-Anhydrodehydroeldelidine, fragmentation ions, 444
 10,12-Anhydroeldelidine, fragmentation ions, 444
 Anhydroepoxykarasamine (AII-3), 135–136t, 329t
 Anhydrolycaconitine, 458t
 Anhydrolycaconitine (F-2), 263t, 338t
 Anisoylzoachasmaconitine (AIIb-99), 92–93t, 337t
 Anisoyl groups
 carbon-13 chemical shifts, 418t
 proton chemical shift ranges, 383t
 6-O-Anisoylheteratisine, 533t, 546t
 14-O-Anisoylneoline (AIIb-92), 90t, 335t
 Anopterines, biosynthesis, 366f, 369
 Anthranoylation reactions, 479, 481f
 Anthranoyl groups, 7, 383t, 418t
 Anthranoyllycoctonine (BIId-12 / inuline), 209–211t, 335t, 533t, 538t, 547t
 Antiarrhythmic activity, 516–518
 Anticancer effects, 520
 Antidotes, 516
 Antiepileptic activity, 520
 Antifeedant activity, 520
 Anti-inflammatory activity, 514
 8-O-Arachidoylforesaconitine (lipoforesaconitine), 342t
 A ring
 conformation, 456–462
 fragmentation, 439, 440f
 modifications, taxoid synthesis, 494–498
 rearrangements, 484–485, 487f
 sogorine-type fragmentation, 447f, 448
 Aromatic substituent antiarrhythmic effects, 517
 Aromatization of ring D, 502
 Artocorine, 524t, 544t
 Atisanes, biosynthesis, 362, 363f, 365–370
 Atisines, 365–370, 366f, 368f
 aconitine biosynthesis, 362, 363f
 lycoctonine biosynthesis, 362–364, 363f, 368f
Atragene sibirica, 302t
 Atropurpursine (AIIb-90), 88–89t, 338t
 Austroconitine A (AIIa-49), 38–39t
 Austroconitine B (AIIb-100), 93–94t, 336t
 Austrosonitine A (14-acetylsachaconitine), 330t
 Avadharidine (BIId-51), 228t, 339t
 8-O-Azeloxy-14-benzoylaconine (AIIId-7), 131–132t, 341t, 521t
 Baeyer–Villiger oxidations, 367f
 Balfourine (AIIb-129), 104–105t, 337t

- Barbeline (BIII-8), 242t, 332t, 458t
 Barbinidine (BIIc-66), 205t, 333t
 Barbinine (BId-35), 220–221t, 339t, 524t, 544t
 Base peaks, mass spectrometry, 448
 Bataconine (Alb-4), 56–57t
 Bearline (BId-36), 220–221t, 340t, 544t
 Beiwucine (Alc-47), 127–128t, 337t
 Beiwudine (E-10/ acononine), 262t, 335t, 392t
 Beiwutine (Alc-43), 126–127t, 338t
 14-*O*-Benzoylaconine (Alc-21), 115–116t, 336t, 521t, 544t
 14-Benzoylbrowniine (BIa-45), 167t, 335t, 524t
 1-*O*-Benzoylcondelphine, 526t, 544t
 Benzoyl davisinol, 527t
 18-*O*-Benzoyl-14-*O*-deacetyl-18-*O*-demethylpubescenine (BIB-11), 181t, 331t, 540t
 8-*O*-Benzoyl-8-*O*-deacetylcrassicauline A, 526t
 6-*O*-Benzoyldelcorine, 527t, 545t
 14-Benzoyldelcosine (BIa-25 / 14-benzoylilensine), 156–157t, 335t, 528t, 545t
 14-Benzoyldelphonine (Alb-80), 84–85t, 335t
 14-Benzoyl-3-deoxyaconine (Alc-11), 112t, 336t
 14-Benzoyldictyocarpine (BIIc-50 / glaucephine), 200t, 336t, 545f
 14-Benzoyldihydrogadesine (BIa-24), 155–156t, 334t
 6-Benzoyldeldelidine, 531t, 544t
 14-*O*-Benzoyl-8-ethoxybikhaconine, 457t
 14-*O*-Benzoyl-8-ethoxybikhaconine (kongboenine), 85–86t, 336t
 14-Benzoyl-8-*O*-ethylaconine (Alc-27 / spicatine A / 8-*O*-ethylbenzoylaconine), 117t, 337t
 14-Benzoylgadesine (BII-10), 237t, 334t, 531–532t
 Benzoyl groups (OBz)
 antiarrhythmic effects, effect on, 517–518
 carbon-13 chemical shifts, 418t
 proton chemical shift ranges, 383t
 6-Benzoylheteratisine (D-8), 257t, 333t, 533t, 546t
 14-Benzoylilensine *see* 14-Benzoyldelcosine
 1-*O*-Benzoylkarakoline, 534t, 544t
 1-Benzoylkarasamine (AIIa-55), 40–41t, 333t
 14-Benzoylmesaconine (Alc-20), 115t, 336t
 14-*O*-Benzoyl-8-methoxybikhaconine, 457t
 14-*O*-Benzoyl-8-methoxybikhaconine (Alb-81), 84–85t, 335t
 14-Benzoylneoline (Alb-73), 82–83t, 334t
 14-Benzoylnudicaulidine, 334t
 14-*O*-Benzoylperegrine (Alb-70), 81t, 335t
 14-Benzoylsachaconitine (AIIa-56), 40–41t, 384t
 14-*O*-Benzoyltaikosamine (BIa-49), 169t, 334t
 14-Benzoyltalatizamine (AIIa-57), 40–41t, 334t, 541t, 548t
 antiarrhythmic effects, 518
 α BGT (α -bungarotoxin) competition, 518
 Bicoloridine *see* Alkaloid A
 Bicolorine-6-*O*-acetate (Alb-30), 68–69t, 330t
 Bicolorine-14-acetate (Alb-36), 70t, 330t
 Bikhaconitine (Alb-124), 103–104t, 339t
 Bioactivities, 519–548
 Bioactivity–toxicity relationships, 519
 Biogenesis, 362–374
 C₂₀-diterpenoids, 365–370, 366f, 367f
 Biosynthesis, 362–374
 aconitines, 362–373
 actaline, 364, 364f
 atisanes, 362, 363f
 atisine, 362, 363f
 kauranes, 362, 363f
 lycoctonines, 362–373
 rearranged-type alkaloids, 372, 374, 374f
 secokaraconitine, 372, 373f
 7,17-*seco*-type alkaloids, 372–374, 372f, 373f
 vilmoritine, 372, 373f
 Biotransformations, 482–483
 Blacknidine (BIB-3), 178t, 329t
 Blacknine (BIIc-10), 188t, 330t
 Boat conformations, 461f
 Bonvalol (BIIc-24), 192t, 331t
 Bonvalone (BIIc-37), 196–197t, 331t
 Bonvalotidine A (BIIc-36), 195–196t, 333t
 Bonvalotidine B (BIIc-25), 193t, 332t
 Bonvalotidine C (BIIc-38), 196–197t, 331t
 Bonvalotine (BIIc-35), 195–196t, 333t, 458t
 Brachyaconitine (Alc-37), 124–125t
 Bradycardic effects, 520
 B ring, 484, 498–500
 Brominations, 477, 478f
 Browniine (BIa-31), 161–163t, 332t, 458t, 524t, 544t
 Budelphine (BIV-14), 249t, 332t
 Bullatine C (Alb-37 / 14-acetylneoline / delstaphisagnine), 71–72t, 332t, 539t
 Bullatine E (Alc-33), 122–123t, 333t

- Bullatine F (15 β -hydroxyneoline),
106–107t, 331t
- Bulleyaconitine A, 524t
- Bulleyanitrine A (BIII-12), 243t, 339t
- Bulleyanitrine B (BIV-7), 247t, 339t
- Bulleyanitrine C (BIV-8), 247t, 339t
- α -Bungarotoxin (α BGT), competition, 518
- 14-*t*-Butoxycarbonylbikhaconine, 524t
- 13-*t*-Butoxycarbonylpyrocassicauline A, 526t
- C11–C17 bond cleavage, 489
- C12–C13 bond cleavage, 487
- Caerunine (BIII-6), 241t, 331t, 390t
- Cammaconine (AIIa-20), 28–29t, 329t, 468f
- Campylocine (BII-16), 239t, 331t, 390t
- Campylotene (BIIc-15), 189t, 331t
- Carbon–13 nuclear magnetic resonance
(¹³C-NMR), 393–437
- aconitine-type chemical shifts, 419–428t
 - lactone-type chemical shifts, 435–436t
 - lycoctonine-type chemical shifts,
429–434t
 - pyro-type chemical shifts, 435t
 - rearranged-type chemical shifts, 437t
 - 7,17-*seco*-type chemical shifts, 436–437t
- Carbon skeleton, classification, 5–6
- Cardiac effects, 516–518, 520
- 1,14-*O*-Cardiopetalidine, 524–525t
- Cardiopetalidine (BIIa-1), 145t, 329t, 365,
458t, 524–525t
- Cardiopetaline (AIIa-1), 18t, 329t, 457t, 525t
- Cardiopetamine, 525t
- Cashmiradelphine (septentriodine),
228–229t, 340t
- C₂₀-diterpenoids, C₁₉-diterpenoid
biosynthesis, 362–371
- Chair conformations, 455–456, 461f
- Chasmaconitine (AIIb-85), 86–87t,
337t, 524t
- Chasmanine-14-benzoate, 457t
- Chasmanine (AIIb-20 / Toroko base II),
64–66t, 331t
- biosynthesis, 370, 371f
- Chasmanthine (AIIb-69), 80–81t, 338t, 457t
- Chemical shifts
- carbon–13, 415–418t
 - proton, 381–393
 - characteristic substituent effects, 382t
 - ester groups, selected alkaloids,
384–393t
- Chemotaxonomy, 374–380
- characteristic alkaloids, 378–380
 - definition, 375
 - ester groups, 376–377
 - methoxyl groups, 377–378
 - oxygenated groups, 377
 - structural categorization, 376
- Chirality, 12, 400, 409–410t
- 8-*O*-Cinnamoylgraciline (BII-2), 235t, 333t
- Cinnamoyl groups, proton chemical shifts,
383t
- 14-*O*-Cinnamoylneoline (AIIb-60),
78t, 335t
- 8-*O*-Cinnamoylneoline (AIIb-61), 79t, 335t
- 14-*trans*-Cinnamoylnudicaulidine (BIIa-50),
169t, 335t
- Circinadine A (AIIa-83), 48t, 336t
- Circinadine B (AIIa-28), 31–32t, 331t
- Circinasine^a A (AIIa-74), 45t, 331t, 457t
- Circinasine B (AIIa-80), 47t, 336t
- Circinasine C (AIIa-37), 33–34t, 335t
- Circinasine D (AIIa-73), 45t, 335t
- Circinasine E (AIIa-70), 44–45t, 330t
- Circinasine F (AIIa-81), 47t, 332t, 457t
- Circinasine G (AIIII-9), 140–141t, 335t
- Classification, 5–16
- carbon skeleton, 5–6
 - heirarchy, 9f
 - nitrogen substitutions, 7
 - numbering schema, 5f
 - substituents, 7–16
- Cleavage
- C11–C17 bonds, 489
 - C12–C13 bond, 487
- ¹³C-NMR *see* Carbon–13 nuclear magnetic
resonance
- Code numbers, 343–362
- Columbianine (AIIa-5), 19t, 331t, 524t
- Columbidine (AIIa-21), 28–29t, 331t
- Conaconitine (AIIa-36), 33t, 329t
- Condelphine (AIIa-47), 36–37t, 331t, 457t,
526t, 544t
- Conformation
- crystal conformation, 460f
 - 1,19-epoxy-containing alkaloids, 461
 - ring D, 462–463
- Conformational changes, carbon–13
chemical shifts, 400, 409t
- Consolida* spp., 302–305
- C. ambigua*, 302–303t
 - C. armeniaca*, 303t
 - C. axilliflora*, 303t
 - C. hellespontica*, 303t
 - C. hohenackeri*, 303t

- C. oliveriana*, 303–304t
C. olopetala, 304t
C. orientalis, 304–305t
C. pubescens, 305t
C. raveyi, 305t
C. regalis, 305t
C. scleroclada, 305t
C. stenocarpa, 305t
 Consolidine (BIb-13), 182t, 332t, 526t
 Consolinine (AIb-12), 61t, 331t
ent-Copolydiphosphate (CPP), 362, 363f
 Cope eliminations, *N*-deethylayion reactions, 470
 Corumdephine (BIc-9), 187–188t, 331t
m-CPBA, 473, 474f, 505–507
 CPP *see ent*-Copolydiphosphate
 Crassicaudine (8-acetyl-14-benzoylchasmnine), 82–83t, 336t
 Crassicaulidine (AIIc-4), 108t, 332t
 Crassicauline A (AIb-108), 95–96t, 338t, 526t
 imination reactions, 472, 474f
 Crassicaulisine (15 β -hydroxyneoline), 106–107t
 Crassicausine (AIb-104), 94–95t, 337t
 Crassicautine (AIb-114), 99–100t, 337t
 C ring, 500–507, 502, 508f, 509f
 Crispulidine (AIIa-26), 30–31t, 329t
 Crystallography, 380–464
 Cyclizations, lycoctonine biosynthesis, 363f, 364
 Cyphoplectine (AIIa-98), 53t, 335t

 Davidisine A (BIIa-40), 166t, 331t
 Davidisine B (BIV-5), 246t, 332t
N-Deacetylajadine, 523t
 14-Deacetylajadine *see N*-Acetyldelectine
 Deacetylbanguine (BIb-18), 183t, 332t
 8-*O*-Deacetyl-8-*O*-*t*-butoxycarbonyloxycrauline, 526t
 8-*O*-Deacetyl-8-*O*-13-*di-t*-butoxycarbonyloxycrauline, 526t
 16-Deacetylgeyerline (BIId-27), 217t, 339t
 14-Deacetyl-14-isobutrylajadine (BIId-14), 212t, 339t
 14-Deacetyl-14-isobutrylnudicauline (BIId-31), 219–220t, 340t
 8-*O*-Deacetyl-8-*O*-isopentylcrassicauline, 526t
N-Deacetylappaconitine, acylations, 478, 480f
 14-Deacetylnudicauline (BIId-29), 218–219t, 339t, 539t, 547f
 14-*O*-Deacetylpubescenine (BIb-9), 179–180t, 331t, 540t
N-Deacetylscapconitine (AIIa-89), 50t, 335t
 8-Deacetyl-sungpaconitine, 336t
 8-Deacetylsungpaconitine (AIb-67), 80–81t
 Deacetylswinanine A (BIc-64), 205t, 331t
 8-Deacetylunaconitine (AIb-110), 97–98t, 337t
N-Dealkylations, carbon-13 chemical shifts, 411, 413–414t
 Decomposition products, aconitine, 484
N-Deethylaconitine (AIIc-38), 124–125t, 337t
N-deethylayion reactions, 470–475
N-Deethylchasmnine (AIb-21), 64–65t, 330t
N-Deethylcrassicauline A, 527t
N-Deethyldecosine, 528t
N-Deethyldephatine (BIIa-39), 165t, 331t
N-Deethyldeolsine, 530t
N-Deethyl-*N*-19-didehydroasapconitine (AIII-1), 138–139t, 329t
N-Deethyllycaconitine-*N*-aldehyde (BIV-10), 248t, 339t
N-Deethylmethyllycaconitine (BIId-40), 225t, 338t
N-Deethyl-14-*O*-methylperegine (AIb-45), 73t, 331t
N-Deethylperegine, 330t, 539t
N-Deethylperegine alcohol (AIb-19 / AIb-42), 64–65t, 72–73t, 329t
N-Deethyltalatisamine (AIIa-12), 23–25t, 329t
 Degraded product of delphinine, t458, 459f
 6-Dehydroacetylsepaconitine, 540–541t
 Dehydroacetylaltatisamine, α -fragmentation, 443
 6-Dehydroacosanine (BIIa-75), 176t, 332t
 Dehydrobicoloridine (AII-6), 136t, 331t
 14-Dehydrobrownine (BIIa-74), 176–177t
 Dehydrocardiopetaline (AII-1), 135–136t, 329t
 6-Dehydrolcorine (BIc-34), 195–196t, 332t
 2,3-Dehydroldecosine (BIIa-66), 173–174t, 331t
 14-Dehydroldecosine (BIIa-72 / 14-dehydroliensine / Shimoburo base II), 175t, 331t
 1-Dehydroldephisine (AIb-53), 76t, 333t
 Dehydroldeolsine (BII-13), 238t, 332t, 390t, 530t
 Dehydroldeletatsine (BII-8), 236–237t, 332t
 Dehydroeldelidine (BIc-67), 205–206t, 331t

- Dehydroheteratisine, 533t
 14-Dehydroiliensine (14-dehydrodelcosine), 175t, 331t
 Dehydrotakaosamine, 541t
 14-Dehydrotalatzamine (Ala-39), 33–34t, 330t
 10-Dehydroxy-flavaconitine (spicatine B), 108t
 Delartine *see* Methyllycaconitine
 Delavaines A and B (BId-53), 229–230t, 340t, 545t
 Delbiterine (BIa-37), 165t, 332t
 Delbotine (BIb-4), 179t, 332t, 458t
 Delbruline (BIc-40), 197t, 332t
 Delbrunine (BIc-17), 189–190t, 332t
 Delbruninol (BIc-11), 188t, 331t
 Delbrusine (BIc-42), 197t, 333t
 Delcaroline (BIa-59), 172t, 333t
 Delcoline, 527t
 Delcoridine (BIc-19), 190–191t, 332t
 Delcorine (BIc-21), 190–191t, 332t, 527t, 545t
 acetoxy group eliminations, 464, 465f
 Delcorinine (BIc-13), 189t, 331t
 Delcosine-14-*O*-acetate (14-acetyldelcosine), 154–155t, 333t
 Delcosine (BIa-12 / delphamine / lucaconine / Takao base I), 148–150t, 331t, 458t, 527t, 545t
 Delectine (BId-3), 206–207t, 335t, 528t, 545t
 Delectinine-14-acetate (BIa-22), 155–156t, 333t
 Delectinine (BIa-29), 157–158t, 331t, 528t
 Delelatine (BIc-18), 189–190t, 330t
 Delphamine *see* Delcosine
 Delphatine (BIa-36 / delsonine), 163–164t, 332t, 529t
 Delphelatine *see* Deltaline
 Delpheline (BIc-20), 190–191t, 331t
 Delphidine (Alb-34 / neoline-8-acetate), 70t, 332t
 Delphiguerin, 529t
 Delphinifoline (BIa-10), 148–149t, 331t, 458t
 Delphinine (Alb-83), 85–86t, 336t, 384t, 457t, 467f, 529t
 acylation reactions, 478, 480f
 degraded product, 458, 459f
Delphinium spp., 305–328t
 D. ajacis, 306t
 D. albiflorum, 306t
 D. alpinum, 306t
 D. andersonii, 305t
 D. anhweiense, 306t
 D. anthriscifolium, var. *savatieri*, 306t
 D. araraticum, 307t
 D. barbeyi, 307t, 548t
 D. belladonna, 307t
 D. bicolor, 307t
 D. biternatum, 307–308t
 D. bonvalotii, 308t
 D. brownii, 308t
 D. brunonianum, 309t
 D. bulleyanum, 309t
 D. buschianum, 309t
 D. caeruleum, 309t
 D. campylocentrum, 309–310t
 D. cardinale, 310t
 D. cardiopetalum, 310t
 D. carduchorum, 310t
 D. carolinianum, 310t
 D. cashmerianum, 310t
 D. cheilanthum, 310t
 D. cinereum, 310t
 D. confusum, 310–311t
 D. consolida, 311t
 D. corymbosum, 311t
 D. cossonianum, 311t
 D. crassifolium, 311t
 D. crispulum, 311–312t
 D. cuneatum, 312t
 D. cyphoplectrum, 312t
 D. davidi, 312t
 D. davisii, 312t
 D. delavayi, var. *pogonanthum*, 312t
 D. denudatum, 312t, 543–544t
 D. dictiocarpum, 312–313t
 D. dissectum, 313t
 D. elatum, 313t, 548t
 D. excelsum, 313–314t
 D. fangshanense, 314t
 D. fissum, var. *anatolium*, 314t
 D. flexuosum, 314t
 D. formosum, 314t
 D. geyeri, 314t
 D. giraldui, 314–315t
 D. glaucescens, 315t
 D. gracile, 315–316t
 D. grandiflorum, 316t
 D. gueneri, 316t
 D. gyalanum, 316–317t
 D. hispanicum, 304–305t
 D. iliense, 317t
 D. kamaonense, var. *glabrescens*, 317t
 D. laxicymosum, 317t
 D. leroyi, 317t

- D. linearilobum*, 317t
D. macrocentron, 317–318t
D. menziesii, 318t
D. mollipilum, 318t
D. munzianum, 318t
D. nordhagenii, 318t
D. nudicaule, 318–319t
D. nuttallianum, 319–320t
D. occidentale, 320t, 548t
D. omeiense, 320–321t
D. oreophilum, 321t
D. orientale, 321t
D. orthocentrum, 321t
D. pacific, 321t
D. pentagynum, 321–322t
D. peregrinum, 322t
D. pictum, 322t
D. poltaratskii, 322t
D. potaninii, 322–323t
D. pylzowii, 323t
D. pyramidale, 323t
D. regalis, 323t
D. retropilosum, 323t
D. rotundifolium, 323–324t
D. roylei, 324t
D. scabriflorum, 324t
D. schmalhauseni, 324t
D. shawurense, 324t
D. siwanense, var. *leptopogon*, 324–325t
D. souliei, 325t
D. speciosum, 325t
D. stapeliosum, 325t
D. staphisagria, 325–326t
D. taliense, 326t
D. tamarae, 326t
D. tatsienense, 326t
D. ternatum, 326t
D. tiantaishanense, 327t
D. tongolense, 327t
D. tricornis, 327t
D. trifoliolatum, 327t
D. triste, 327t
D. uncinatum, 327t
D. uralense, 327–328t
D. verdunense, 310t
D. vestitum, 328t
D. virescens, 328t
D. virgatum, 328t
D. winklerianum, 328t
D. yunnanense, 328t
D. zalil, 328t
 lycotonines, 369–370
 Delphiperegrine (B1b-23), 185t, 336t
 Delphirine (A1b-6 / 1-epi-neoline), 56t, 57–60t, 330t
 Delphisine (A1b-52 / neoline-8,14-diacetate), 76t, 334t, 457t, 468f
 acylations, 478, 480f
 Delphonine, *N*-oxidations, 469–470
 Delpoline (A1a-43), 35–36t, 329t
 Delretine (B1c-56), 202–203t, 334t
 Delsemidine *see* Methyllycaconitine
 Delsemine A (B1d-61), 232–233t, 340t
 Delsemine B (B1d-62), 232–233t, 340t, 529t
 Delsemine (B1d-63), 232–233t, 340t
 Delsine *see* Lycoctonine
 Delsoline (B1a-18 / acomonine), 152–154t, 332t, 458t, 468t, 530t
 Delsonine (delphatine), 163–164t, 332t, 529t
 Delstaphidine (A11-8), 137t, 333t, 386t
 Delstaphigine (A1b-84), 85–86t, 335t
 Delstaphingine, 467f
 Delstaphinine (A11-7), 137t, 330t
 Delstaphisagrine (bullatine C), 71–72t, 332t, 539t
 Delstaphisagrine (A1b-51), 75t, 333t
 Delstaphisine (A1b-50), 75t, 333t
 Delstaphisinine (A1b-33), 69–70t, 333t
 Deltaline (B1c-53 / delphelatine / eldeline), 201–202t, 333t, 389t, 530t, 545t
 hydroxyl group eliminations, 464, 465f
 taxoid synthesis, 491, 493f, 494f, 507–514
 Deltamine (B1c-52 / eldelidine), 201t, 332t, 531t, 545t
 acetoxyl group eliminations, 464, 465f
 Deltatsine (B1b-7), 179–181t, 332t, 530t
 Delterine (B1a-58), 172t, 332t
 Delvestidine (B1d-10), 209–210t, 336t
 Delvestine (B1d-9), 208–209t, 335t, 458t
 1-Demethoxybikhaconine, 524t
 16-Demethoxydelavaines A and B (B1d-54), 229–230t, 339t
 16-Demethoxymethyllycaconitine (B1d-45), 226t, 338t
 18-Demethoxypubescentine (B1b-14), 182t, 332t
 14-Demethyl-14-acetylanhweidelphinine (B111-13), 244t, 339t
 14-Demethylajacine, 523t
 O-Demethylation reactions, 466–468
 18-Demethyl-14-deacetylpubescence (B1b-5), 179t, 331t
 Demethyldelecorine, 527t

- 6-Demethyldephatine (acosanine),
161–162t, 332t
- 16-Demethyldeolsoline, 331t
- 6-Demethyldeolsoline (exceconitine), 151t,
331t
- Demethylenedelpheline (BIa-35), 163–164t,
330t
- Demethylenedeltamine *see*
Demethylenedelididine
- Demethylenedelididine (BIa-56 /
demethylenedeltamine), 171t, 331t,
531t
- 1-Demethylhyaconitine (AIIc-13), 113t, 336t
- 14-Demethyl-14-
isobutrylanhweidelphinine (BIII-14),
244t, 340t
- 14-Demethyllycaconitine (BIId-20), 214–215t,
338t
- 6-O-Demethylneoline (AIIb-4), 56–57t
- 18-Demethylpubescenine (BIIb-6), 179t, 332t,
540t
- 1-O-Demethyltricornine (BIa-17), 152t, 333t
- 14-Demethyltuguaconitine, 543t
- 1-Demethylwinkleridine (BIa-3), 145t, 330t
- Denudatines
actaline biosynthesis, 364, 364f
biogenetic relationships, 365–370, 366f,
367f
- 14-Denzoylnudicaulidine (BIa-46), 168t
- Deoxyaconitine (AIIc-8), 109–111t, 337t, 385t
- 6-Deoxydelcorine (BIIc-7), 187–188t, 332t,
527t, 544t
- 6-Deoxydelpheline (BIIc-6 / occidentaline),
186–187t, 330t
- Deoxydeolsoline (BIa-38), 165t, 331t
- 3-Deoxyjesaconitine (AIIc-12 /
deoxyjesaconitine), 112t, 339t
- 13-Deoxyludaconitine (AIIb-77), 83–84t,
112t, 335t, 384t
- 18-Deoxylycoctonine (BIa-34), 163–164t, 331t
- Desacetyl-6-epipubescenine (BIIb-10), 181t,
331t
- Desbenzoylpyroaconitine (CII-2), 252–253t,
332t
- N-Desmethyl-N-formyl-8-deacetyl-15 β -
hydroxydelphinine, 457t, 459f
- Desoxymesaconitine *see* Hyaconitine
- 1,14-Diacetyl-10-hydroxyisotalatizidine,
458t, 459f
- 3,15-O-Diacetylaconitine, 522t
- 3,15-O-Diacetylbenzoylaconitine, 522t
- 1,14-O-Diacetylcardiopetamine, 525t
- N-O-Diacetyldelectine, 528t, 544t
- 3,8-Diacetylfalconerine, 531t
- Diacetylheteratisine (D-7), 257t, 332t
- 1,14-Diacetylneoline (AIIb-35), 70t, 334t
- 3,13-Diacetylpsuedaconitine, 522t
- Diacetylpsuedaconitine (AIIb-127), 104–105t,
341t, 522t
- Diacetylatalisamine, 443, 542t
- Diacetylylunaconitine, taxoid synthesis,
508f
- 3,15-Dibenzoylaconitine, 522t
- 8,14-Dibenzoylbikhaconine, 524t
- Dicoloridine (alkaloid A), 72–73t
- Dictyocarpine (BIIc-48), 199–200t, 333t,
388–389t, 458t, 461f
- Dictyocarpine (BIIc-47), 199t, 331t,
530t
- Dictysine, 530t
- 1-O,19-Didehydrotakaosamine (BII-6),
235–236t, 330t
- 13,15-Dideoxyaconitine (AIIb-78 /
hemsleyanine), 83–84t, 337t
- Di-ester containing alkaloids, stability,
483–484
- Dihydrogadesine (BIa-13), 151t, 330t
- Dihydromonticamine, 538t
- Dihydromonticoline, 538t
- Dihydropentagynine (AIIb-9), 57–58t, 329t
- 7,8-Dihydroxyl/18-anthranoyl lycoctonine
subtypes (BIId), 10f, 206–234
- 7,8-Dihydroxyl lycoctonine subtypes (BIa),
10f, 145–177t
- 6,14-Dimethoxyforesticine (AIIb-24), 66–67t,
332t
- 14-Dimethyldeboxine, 527t
- 16,18-Di-O-acetyl-16,18-diacetyl
demethyldephinine, 457t, 459f
- 7,18-Di-O-methyl-lycoctonine (BIIb-22), 185t
- 7,8-Dioxymethylene groups, lycoctonine
subtypes (BIIc), 10f, 185–206t
- Distribution of diterpenoid alkaloids, 16–17
- Docetaxel (Taxotere[®]), 491
- Dolichotine A (AIIa-61), 42t, 336t
- Dolichotine B (AIIa-63), 42t, 337t
- Dolichotine C (AIIa-66), 43t, 336t
- Dolichotine D (AIIId-1), 129–130t, 341t
- Dolichotine E (AIIId-4), 130–131t, 341t
- Double bond containing pyro-subtypes
(CI), 11f, 250–252t
- Double bonds, 12, 14, 399t
- D ring, 462–463, 515–516
- Duclouxine (AIIb-86), 86–87t, 337t

- EI-MS *see* Electron-ionization mass spectrometry
- Eladine (BIc-22), 192t, 330t
- Elanine (BIc-32), 219–220t, 341t
- Elasine (BIc-54), 201t, 333t
- Elatidine, lactam synthesis, 472, 473f
- Elatine (BIc-41), 225t, 340t, 389t, 530t, 545t
N-oxidations, 473, 474f
- Eldelidine *see* Deltamine
- Eldeline *see* Deltaline
- Electron-ionization mass spectrometry (EI-MS), 438, 439–447, 450–454
- Electrospray ionization mass spectrometry (ESI-MS), 450–454
- Elimination reactions, 464–466
- 6-Epichasmanine (Alb-22), 66–67t, 331t
- 1-Epi-crassicaudine, 336t
- 1-Epicrassicaudine (Alb-75), 82t
- 1-Epi-deacetylaconitine (Alc-23), 116t, 336t
- 1-Epi-delphisine, 457t, 459f
- 6-Epiforesticine (longtouconitine B), 62t, 330t, 457t
- 1-Epi-12 β -hydroxykarasamine (AIa-35), 33t, 329t
- 15-Epi-isodelphonine, 457t, 459f
- Epimerization, prevention, 478–479
- 1-Epi-neoline (Alb-6 / delphirine), 56t, 57–60t, 330t
- 6-Epi-neolinine-14-acetate (Alb-47), 74t, 332t
- 6-Epi-neolinine (Alb-11), 61t, 330t
- 6-Epi-pubescenine (BIb-15), 182t, 333t
- 16-Epi-pyroaconine (CII-1), 252–253t, 332t, 391t
- 16-Epi-pyroaconitine (CII-3), 252–253t, 522t
- 16-Epi-pyrojesaconitine (CII-7), 254t, 337t
- 16-Epi-pyromesaconitine (CII-5), 253t
- Epitalatizidine, 542t
- 1,19-Epoxy-containing alkaloids, 439, 440f, 447–448, 461–462
- ESI-MS *see* Electrospray ionization mass spectrometry
- Ester-exchange reactions, 482
- Esterification reactions, 415t
- 8-Ethoxysachaconitine (AIa-18), 27t, 330t
- 8-O-Ethylbenzoylaconine (14-O-benzoyl-8-O-ethylaconine), 117t, 337t
- 14-O-Ethylbikhaconine, 524t
- N-Ethyl groups, 12
- 8-O-Ethylunaconitine (acoforestinine), 100–101t
- Exceconitine (BIa-15 / 6-demethyldelsoline), 151t, 331t
- Excelsine, 531t
- Expansion reactions, ring B, 484
- Ezochasmaconitine (Alb-76), 83–84t, 336t
- Ezochasmanine (Alb-26), 67–68t, 332t
- Falconericine (Alb-120), 101–102t, 338t
- Falconeridine (Alb-119), 101–102t, 337t
- Falconerine (Alb-121), 102t, 337t, 468f, 531t
- Faleoconitine (AIV-6), 143t, 340t, 458t
- Feniculatine C (AIa-62), 42t
- Finetiadine (BIc-49), 228t, 340t
- Flaconitine (CI-6 / 3-acetylaconitine), 118–120t, 251t, 337t, 339t, 391t, 522t
- Flavaconidine (AIV-9), 143–144t, 337t, 387t
- Flavaconitine (Alc-41 / AIV-4), 125–126t, 143t, 336t, 337t, 387t
- Foresaconitine (Alb-94 / vilmorrianine C), 91–92t, 337t
- Foresticine (Alb-13), 62t, 330t, 384t
- Forestine (Alb-102), 93–94t, 336t, 385t
- Formamide groups, 394
- Forsticine, 476, 477f
- Fragmentation
aconitine alkaloids, 451–453
A ring, mass spectrometry, 439, 440f
- α -Fragmentation, 439–447
aconitine-type, 439, 440f
1,19-epoxy containing alkaloids, 439, 440f, 447–448
fragmentation ions, 441, 443f
lycoctonine-type, 439, 440f
pathways, 441–442f
- Fragmentation ions, 439–447, 450–454
 α -fragmentation, 441, 443f
lactone-type, 444, 445f
lycoctonine-type, 444–446
6-OAc-containing alkaloids, 444
rearranged-type, 444, 445f
- Francheline (E-6), 260t, 330t
- Franchetine (E-1), 15, 16t, 259t, 334t, 392t
- Functional groups
carbon-13 chemical shifts, 415–418t
molecular ion/base peaks, 448
proton chemical shift ranges, 382t
- Functionalizations, 365, 370, 371f
- 6-O-Furoylheteratisine, 533t, 546t
- Fuziline (15 α -hydroxyneoline), 106–107t, 331t, 457t
- Gadeline (BII-11), 237t, 334t
- Gadenine (BIa-54), 170t, 334t, 531t

- Gadensine, α -fragmentation, 447f
 Gadesine (BII-5), 235–236t, 330t, 458t, 461f, 531–532t
 Gas chromatography-mass spectrometry (GC-MS), 438, 439t
 Geniconitine (AIIb-96), 91t, 335t
 Geniculatine A (AIIb-93), 90t, 337t
 Geniculatine B (AIIb-118), 101–102t, 336t
 Geniculatine C, 337t
 Geniculatine D (AIIa-64), 43t, 335t
 Geniculine (AIIb-113), 99–100t, 338t
 Genicunine A (AIIa-41), 34–35t, 329t
 Genicunine B (AIIa-32), 32t, 329t
 Genicunine C (AIIa-38), 33–34t, 329t
 Geyerline, 545–546t
 Gigactonine (BIIa-16), 152–153t, 331t, 387t, 532t
 Gigoktonine, 532t
 Giralidine A (BIIa-65), 173–174t, 330t, 388t
 Giralidine B (BIIa-68), 174t, 331t
 Giralidine C (BIIa-69), 174t, 334t
 Giralidine D (BIIb-17), 183t, 330t
 Giralidine E (BIIa-67), 174t, 332t
 Giralidine F (BIIa-70), 175t, 330t
 Giralidine G (BIIb-57), 230–231t, 341t
 Giralidine H (BIIb-58), 231–232t, 341t
 Glabredelphinine (BIIa-63), 173t, 329t
 Glaucedine (BIIa-51), 169t, 334t
 Glaucenine (BIIc-49), 200–201t, 335t
 Glaucephine (14-benzoyldictyocarpine), 200t, 336t, 545f
 Glaucenine (BIIc-51), 200–201t, 335t
 Claudelsine (BIIb-38), 221t, 339t, 389t
 Glycol alcohol oxidations, 477–478, 479f
 Graciline (BII-1), 235t, 329t
 Gracinine (BIIa-26), 156–157t, 334t
 Grandifloricine (BIIb-34), 220–221t, 338t
 Grandiflorine (BIIb-28 / uraline), 218t, 339t, 546t
 Grandifloritine (BII-15), 238t, 338t
 Grob fragmentations, 7, 481–482, 488–489
 Guayewuanine A (AIIa-84), 48t, 335t
 Guayewuanine B *see* Yunaconitine
 Guenerine (AIII-7), 140–141t, 331t
 Gyalanines A and B (BIIb-55), 230–231t, 340t
 Gymnaconitine (AIIa-65), 43t, 336t
 H-8/CO-15-pyro subtypes (CII), 252–254t
 Habaenine (AIIb-112), 99–100t, 337t
 Habaenine A (AIV-3), 142t, 338t
 Habaenine C (AIV-2), 142t, 338t
 Hierarchy of classification, 9f
 Hemsleyadine (AIIa-75), 45t, 336t, 457t
 Hemsleyanine A (AIIa-79), 47t, 335t
 Hemsleyanine B (AIIa-78), 46t, 331t
 Hemsleyanine C (AIIa-71), 44–45t, 330t
 Hemsleyanine D (AIIa-72), 44–45t, 335t
 Hemsleyanine (13,15-dideoxyaconitine), 83–84t, 337t
 Hemsleyanisine (AIIa-76), 46t, 335t, 532t
 Hemsleyasine (AIIa-82), 48t, 336t
 Hemsleyatine (AIIb-28), 68–69t, 332t
 Heptacyclic core systems, structure determination, 455
 Heteratisine (D-5 / zeravschanine), 256t, 329t, 458t, 532–533t, 546t
 Heteratisine N-oxide, 533t
 Heterophyllidine (D-4), 256t, 329t
 Heterophylline (D-1), 255t, 329t
 Heterophyllinine A and B, 533t
 Heterophyllisine (D-2), 255t, 329t, 391t, 533t
 Hetidane biosynthesis, 366f, 368–369
¹H-NMR *see* Hydrogen-nuclear magnetic resonance
 Hokbusine A (AIIc-17 / jianyouaconitine), 114t, 336t
 Hokbusine B (AIIa-46), 36–37t, 329t
 Homochasmanine (AIIb-25), 67–68t, 332t
 Human intestinal bacteria, biotransformations, 482–483
 Hydrogen-nuclear magnetic resonance (¹H-NMR), 381–393
 10 β -Hydroxyaconitine (aconifine), 126–127t, 339t, 521t
 16 β -Hydroxycardiopetaline (AIIa-3), 18t, 329t
 10-Hydroxydelsoline (tursoline), 171t, 333t
 2-Hydroxydeoxyaconitine (AIIc-48), 127–128t, 338t
 3-Hydroxyfranchetinea (E-5), 260t, 334t
 13-Hydroxyfranchetinea (E-7), 261t, 334t
 10-Hydroxyisotalatizidine (AIIa-31), 32t, 330t
 12 β -Hydroxykarasamine-8-O-acetate (AIIa-54), 39–40t, 331t
 12 β -Hydroxykarasamine (AIIa-34), 33t, 329t
 7-Hydroxyl/8-methoxyl groups, lycoctonine subgroup (BIIb), 10f, 178–185t
 Hydroxyl groups (OH), 13
 antiarrhythmic effects, 517
 carbon-13 chemical shifts, 411, 414t
 elimination reactions, 464–466
 N-oxidations, 469
 oxidation reactions, 475–477

- 18-Hydroxy-14-*O*-methylgadesine, 458t
18-Hydroxy-14-*O*-methylgadesine (BII-12), 237–238t, 331t, 532t
10-Hydroxymethyllycaconitine (BId-44), 226t, 340t
15 α -Hydroxyneoline (AIC-2 / fuziline / senbusine C), 106–107t, 331t, 457t
15 β -Hydroxyneoline (AIC-3 / bullatine F / crassicaulisine / nagarine), 106–107t, 331t
10-Hydroxynudicaulidine (BIa-57), 171t, 331t
10-Hydroxyperegrine (AIB-59), 78t, 332t
9-Hydroxysenbusine A (AIB-5), 56t, 331t
3-Hydroxytalatisamine (AIA-27), 30–31t, 330t
10-Hydroxytalatizamine (AIA-33), 32t, 330t
Hypaconitine (AIC-9 / desoxymesaconitine), 109–111t, 337t, 385t, 533t
Hypotensive effects, 520

Ibukinamine (BIa-64), 173–174t, 330t, 458t
Ilidine (BIC-32), 194–195t, 331t
Iliensine *see* Delcosine
Imination reactions, 470–475
 3-acetylpsuedaconine, 470, 471f
 14-acetylalatisamine, 472, 474f
 crassicauline A, 472, 474f
 lappaconitine, 472, 473t
 talatisamine, 472, 473t
Imine-subtypes, aconitine-type (AIII), 10f, 138–141t
Imine-subtypes, lycoctonine type (BIII), 10f, 240–245t
Immonium salts, 368f, 473, 474f
Indaconitine (AIB-89), 88–89t, 337t, 385t
Introduction, sugar groups, 498
Inula royleana, 328t
Inuline *see* Anthranoyllycoctonine
Isoaconitine *see* Yunaconitine
Isobutyrate groups, 14
Isobutyryl groups, proton chemical shift ranges, 383t
Isobutyryloxy groups, carbon-13 chemical shifts, 418t
14-Isobutyrylnudicaulidine (BIa-52), 170t, 333t
Isodelectine (BId-1), 206–207t, 335t
Isodelpheline (tongoline), 196–197t, 331t
Isodelphinine, 336t
Isohemsleyanisine (AIA-77), 46t, 335t, 532t
Isolappaconitine, 537t

Isopentanonyl group chemical shifts, 383t
Isopentanonyloxy group chemical shifts, 418t
Isotalatizidine (AIA-9), 20–22t, 329t, 542t, 548t
 N-deethylation reactions, 470, 471f
 α -fragmentation, 447
 methoxyl group eliminations, 465, 466f
 oxidation reactions, 476, 477f

Jesaconitine (AIC-32), 122–123t, 339t, 457t
 conformation, 462, 463
Jianyouaconitine (hokbusine A), 114t, 336t
Jiufengdine (BId-7), 208–209t, 338t
Jiufengsine (BId-65), 234t, 340t
Jiufengtine (BId-8), 208–209t, 335t

Kako-bushi-matsu, 302t
Karacolidine (AIA-30), 31–32t, 329t
Karacolone *see* Karakoline
Karakanine (AII-2), 135–136t, 329t, 386t
Karakoline (AIA-8 / karacolone / vilmorrianine B), 20–22t, 329t, 533–534t, 546t
 biogenesis, 365, 457t
Karasamine (AIA-22), 29–30t, 329t, 534t
Kauranes, 362, 363f, 365–370, 366f, 368f
 veatchine synthesis, 368–369
Kongboendine (E-3), 259t, 335t
Kongboenine (14-*O*-benzoyl-8-ethoxybikhaconine), 85–86t, 336t
Kongboensine (AIA-40), 34–35t, 329t
Kongboentine A (AIA-15), 26–27t, 329t
Kongboentine B (AIB-72), 81t, 334t, 384t

Lactam synthesis, 472, 473f
Lactone-type alkaloids (D), 5–6, 11f, 15, 255–258t, 343–362
 carbon-13 chemical shifts, 435–436t
 fragmentation ions, 444, 445f
 quaternary carbon chemical shifts, 395t
 X-ray crystallography, 458t
Lappaconidine, 534t
Lappaconine, 534t, 537t, 546–547t
 biogenesis, 367f
 oxo-Lappaconine, 537t
Lappaconitine, 467f, 534–537t
 antiarrhythmic effects, 516
 bromination, 477, 478f
 glycol alcohol oxidation, 477, 478f
 imination reactions, 472, 473t
 N-oxidation reactions, 473
Lasianine (AIC-36), 123–124t, 333t
Lasiansine (AIB-27), 67–68t, 331t

- Laxicymine (BII-18), 239t, 331t
 Laxicyminine (BII-17), 239t, 330t
 Laxicymisine (BIc-16), 189–190t, 331t
 Leroyine-14-*O*-acetate (BIa-6),
 146t, 330t
 Leroyine (BIa-2), 145t, 329t
 Leucanthumsine A (Alb-63), 79t, 337t
 Leucanthumsine B (Alb-62), 79t, 335t
 Leucanthumsine C (Alb-23), 66–67t, 330t
 Leucanthumsine D (AIII-3), 138–139t, 330t
 Leucanthumsine E (Alb-88), 88–89t, 337t,
 384t
 Leucophine, 537t
 Leucostine A (BIa-42 / 6-*O*-
 acetyl demethylenedelcorine), 166t,
 333t
 Leucostine B (BIa-62), 173t, 332t
 Leueandine (E-4), 260t, 334t
 Leueantine A (Alb-66), 79–80t, 338t
 Leueantine B (Alb-65), 79–80t, 337t
 Leueantine C (Ala-67), 43–44t, 334t
 Leueantine D (Alb-64), 79–80t, 335t
 Liaconitine A (Alb-105), 94–95t, 338t
 Liaconitine B (Alb-106), 95–96t, 340t
 Liaconitine C (Alb-107), 95–96t, 337t
 Liljestrandinine (Ala-44), 35–36t, 329t
 Liljestrandisine (Ala-42), 34–35t, 329t
 Linearilobin (Ala-97), 53t, 339t
 8-*O*-Linolenoyl-14-*O*-anisoylbikhaconitine
 (lipo-14-*O*-anisoylbikhaconitine),
 129–130t, 342t
 8-*O*-Linolenoylaconitine (lipoaconitine),
 134–135t, 342t
 8-*O*-Linolenoylhypaconitine
 (lipohypaconitine), 341t
 8-*O*-Linolenoylindaconitine
 (lipoindaconitine), 341t
 8-*O*-Linolenoylmesaconitine
 (lipomesaconitine), 341t
 8-Linolenylfalconerine, 531t
 8-*O*-Linoleoyl-3-deoxyaconitine
 (lipo-3-deoxyaconitine), 341t
 8-*O*-Linoleoylbikhaconitine
 (lipobikhaconitine), 342t
 8-*O*-Linoleoylforesaconitine
 (lipoforesaconitine), 341t
 8-*O*-Linoleoylhypaconitine
 (lipohypaconitine), 341t
 8-*O*-Linoleoylmesaconitine
 (lipomesaconitine), 341t
 8-*O*-Linoleoylpseudaconitine
 (lipopseudaconitine), 342t
 8-*O*-Linoleoylyunaconitine
 (lipoyunaconitine), 342t
 Lipo-3-deoxyaconitine (AId-10), 132–133t
 Lipoaconitine (AId-13 / 8-*O*-
 linolenoylaconitine), 134–135t, 342t
 Lipo-alkaloid aconitine subtypes (AId), 10f,
 129–135t
 Lipo-alkaloids, 12, 129–135t, 453
 synthesis, 482
 Lipo-14-*O*-anisoylbikhaconine (AId-3 /
 8-*O*-linolenoyl-14-*O*-
 anisoylbikhaconitine), 129–130t, 342t
 Lipobikhaconitine (AId-5), 130–131t, 342t
 Lipodeoxyaconitine (AId-10), 132–133t,
 341t, 342t
 Lipoforesaconitine (AId-2), 129–130t, 341t,
 342t
 Lipohypaconitine (AId-11), 132–133t, 341t
 Lipoindaconitine (AId-6), 130–131t, 341t,
 342t
 Lipomesaconitine (AId-12), 132–133t, 341t,
 342t
 Lipopseudaconitine (AId-9), 131–132t, 341t,
 342t
 Lipoyunaconitine (AId-8), 131–132t, 342t
 Liwaconitine (Alb-109), 97–98t, 340t, 385t
 Long-chain fatty acid esters, at C-8, 12
 Longtouconitine A (Alb-103), 94–95t, 338t
 Longtouconitine B (Alb-15 /
 6-epiforesticine), 62t, 330t, 457t
 Lucaconine *see* Delcosine
 Luciculine, 537t
 Ludaconitine (Alb-87), 86–87t, 336t
 Lycaconitine (BIc-24), 215–216t, 339t, 537t
 semisynthesis, 490–491
 Lycoctonine (BIa-30 / delsine / royaline),
 157–161t, 332t, 387t, 537–538t, 547t
 methyllycaconitine semisynthesis, 490
 rearranged product, 458, 459f
 Lycoctonine-type alkaloids (B), 5–6, 13–14,
 454
 acylation reactions, 479, 481f
 amide-subtypes, 245–249t
 amine-subtypes, 13–14, 145–249t
 biosynthesis, 362–371
 chemical shifts, 395t, 407–408t, 429–434t
 code numbers, 343–362
 crystallography, 458t
 cyclization reactions, 363f, 364
 7,8-dihydroxyl/18-anthranoyl-subtypes,
 206–234
 7,8-dihydroxyl groups, 145–177t

- 7,8-dioxymethylene group-subtypes, 185–206t
 α -fragmentation, 439, 440f
 fragmentation ions, 444–446
 7-hydroxyl/8-methoxyl group-subtypes, 178–185t
 imine-subtypes, 240–245t
N,O-mixed acetal-subtypes, 235–239
Lycoctonum gigas, 277t
- Macrorrhynine A (AIII-5), 139–140t, 336t
 Macrorrhynine B (AIII-8), 140–141t, 337t
 Mannich reactions, C₂₀/C₁₉ alkaloid biogenesis, 366f, 367f
- Mashurinine (AIIc-31), 122–123t, 340t
 Mass spectrometry (MS), 438, 439–454
 applications, 439t
 base peaks, 448
 lycoctonines, 454
 molecular ion peaks, 448
 soft ionization, 450–454
 structure determination, 449–450
- Merckonine (AIII-10), 141t, 337t, 387t
 Mesaconitine, 457t
 Mesaconitine (AIIc-28), 118–121t, 337t, 538t, 547t
- Methanol, di-ester compound stability, 483–484
- 3'-Methoxyacoforestinine (AIIb-132), 105–106t, 339t
- 1-Methoxy-3,13-diacetyl-14-methanesulfonylpyrobikhaconine, 524t
- 18-Methoxygadesine (BII-7), 236–237t, 331t, 532t
- 18-O-Methoxygigactonine, 532t
- 8-Methoxyl/7-hydroxyl group lycoctonine subtypes (BIb), 10f, 178–185t
- Methoxyl groups (OMe), 13–14
 antiarrhythmic effects, 517
 chemotaxonomy, 377–378
 eliminations, 464–466
 molecular ion peaks, 448
- 8-Methyl-10-hydroxylycoctonine (BIb-21), 184t, 333t
- 14-(2-Methylbutyryl)-nudicaulidine (BIa-48), 168t, 334t
- 8-O-Methylcolumbiapine (raveyine), 26–27t, 329t, 524t
- 8-O-Methylconsolarine (BIb-8), 179–180t, 330t, 526t
- Methyldecoline, 527t
- Methyldephatine, 529t
- 1-O-Methyldephisine (AIIb-54), 76t, 334t
- 18-O-Methyldeleterine (BIa-61), 173t, 333t
- 7,8-Methylenedioxy-containing compounds (BIc), 7, 10f, 378, 498
 fragmentation ions, 446
- 14-O-Methylforesticine (AIIb-17), 63t, 331t
- Methylgymnaconitine (AIIa-68), 43–44t, 336t
- 8-O-Methylhypaconine (AIIc-14), 113t, 333t
- 14-O-Methylisotalatizidine (AIIa-23), 29–30t, 330t
- 8-O-Methylkarakoline (AIIa-14), 26–27t, 329t, 534t
- 8-O-Methylkarasamine (AIIa-6), 19t, 329t
- Methyllycaconitine (BIId-39 / delartine / delsemidine), 221–224t, 339t, 389t, 547t
 semisynthesis, 490–491
- 8-O-Methyllycaconitine (oreaconine), 217t, 339t
- 7,18-di-O-Methyllycoctonine, 333t
- 8-Methyllycoctonine (BIb-19), 184t, 332t
- Methyllyconitine, 538t
- 14-O-Methylperegrine (AIIb-44), 73t, 332t, 539t
- 18-O-(2-Methyl-4-*oxo*-4*H*-quinazolin-3-yl) benzoyllycoctonine (BIId-64), 234t, 340t
- 8-O-Methylsachaconitine (AIIa-16), 27t, 329t
- 8-O-Methyltalatizamine (AIIa-17), 27t, 330t
- 8-O-Methyl-veratrolypseudaconine (AIIb-128), 104–105t, 339t
- Mithaconitine (CI-5), 251t, 335t
- N,O*-Mixed acetal-aconitine subtypes (AII), 10f, 135–138t
- N,O*-Mixed acetal-lycoctonine subtypes (BII), 10f, 235–239
- N,O*-Mixed acetal synthesis, 470–475
 from *N*-oxides, 475
- Moieties, chemical shift ranges, 397–398t
- Molline (BIc-44), 198t, 332t
- Monticamine, 538t
- Monticoline, 538t
- Multidrug resistance effects, 520
- Munzianine (AIIb-14), 62t, 330t, 384t
- Munzianone (AIIb-1), 55t, 330t
- NACHR *see* Nicotinic acetylcholine receptors
- Nagadine (AIII-2 / pengshenine B), 138–139t, 329t, 386t
- Nagarine (15 β -hydroxyneoline), 106–107t, 331t

Napellines

- actaline biosynthesis, 364f
- biogenetic relationships, 365–370, 366f, 367f

NBS, *N*-oxidations, 473, 475f

Neojiangyouaconitine (A1c-15), 113t, 336t

Neoline-8-acetate (delphidine), 70t, 332t

Neoline (A1b-7), 57–60t, 330t, 539t

- biosynthesis, 370, 371f

- proton transfer in fragmentation, 453f

Neoline-8,14-diacetate *see* Delphisine

Neolinine (A1b-10), 61t, 330t

Neural inhibition, 515–516

Nevadenine (A11-4), 136t, 329t

Nevadensine (B11-4), 235–236t, 330t

Nicotinic acetylcholine receptors (nAChR), inhibition, 490–491

6-*O*-Nitrobenzoylheteratisine, 533t, 546t

Nitrogen atoms

- α -fragmentation, 439, 440f
- substituent antiarrhythmic effects, 517

Nitrogen substitutions, classifications, 7

Nitrones, formation, 470–475

NMR *see* Nuclear magnetic resonance

Nonoxygenation at C-6, aconitine subtypes (A1a), 10f, 18–54t

Nonoxygenation at C-15/oxygenation at C-6, aconitine subtypes (A1b), 10f, 55–106t

Nor-*oxo*-aconitine, 522t

Noraconitine, 522t

Nordhagenine, 458t

Nordhagenine A (B1c-8), 187–188t, 331t

Nordhagenine B (B1c-55), 202–203t, 333t

Nordhagenine C (B1c-23), 192t, 333t

Nuclear magnetic resonance (NMR), 381–437

- carbon 13, 393–437

- hydrogen, 381–393

Nudicaulamine (B1c-5), 186–187t, 331t

Nudicaulidine (B1a-28), 157–158t, 330t

Nudicauline (B1d-30), 218–219t, 340t, 539t, 547t

Numbering schema, 5f

Nuttallianine (A1b-39), 71t, 332t

OAc *see* Acetoxy groups

OAn *see* Anthranoyl groups

OAs *see* Anisoyl groups

OBz *see* Benzoyl groups

Occidentalidine (B1a-47), 168t, 334t

Occidentaline (6-deoxydelpheline), 186–187t, 330t

Occurrences, 17–328

aconitine-type alkaloids, 18–144t

Aconitum Spp., 266–302t

Compositae, 328t

Consolida Spp., 302–305t

Delphinium Spp., 305–328t

lactone-type alkaloids, 255–258t

lycoctonine-type alkaloids, 145–249t

plant species, 266–328

pyro-type alkaloids, 250–254t

rearranged-type alkaloids, 263–264t

7,17-*seco*-type alkaloids, 259–262t

3 α -OH containing alkaloids, ring A conformation, 462

Olefinic carbons, chemical shifts, 394

Olefinic ketones, taxoid synthesis, 511–514

Olefins, oxidative cleavage, 367f, 368f

8-*O*-Oleoylaconitine (lipoaconine), 342t

8-*O*-Oleoyl-14-*O*-anisoylbikhaconine (lipo-14-*O*-anisoylbikhaconine), 342t

8-*O*-Oleoylhypaconitine (lipohypaconitine), 341t

8-*O*-Oleoylmesaconitine (lipomesaconitine), 342t

8-*O*-Oleoylpseudaconitine (lipopseudaconitine), 341t

Olividine (B111-3), 240t, 333t, 539t

Olivimine (B111-5), 241t, 331t, 539t

Olyschistine C (A1c-40), 125–126t

Omeienine (B1d-48), 227t, 338t

Oreaconine (8-*O*-methyllycaconitine), 217t, 339t

Orthocentrine (B111-2), 240t, 329t

Ouvrardiantine (A1b-91), 90t, 339t

Oxaziridines

- synthesis, 475, 476f

- taxoid synthesis, 495, 496f

Oxidation reactions

3-acetylpsuedaconine, 477

3-acetyllyunaconitine, 472, 473f

alcohols, 475–477

biogenesis, 367f, 368f

forsticine, 476, 477f

glycol alcohols, 477–478, 479f

hydroxyl groups, 475–477

isotalatizidine, 476, 477f

N-Oxidation reactions, 468–475

carbon-13 chemical shifts, 411, 412t

m-CPBA, 473, 474f

elatine, 473, 474f

lappaconitine, 473

NBS, 473, 475f

- Oxidative cleavage, olefins, 367f, 368f
N-Oxides, *N,O*-mixed acetal synthesis, 475
19-Oxoanthranoyllycoctonine (BIV-6), 246t, 336t
19-Oxodelphatine (BIV-1), 245t, 333t, 390t
 α -Oxodelphinine (AIV-5), 143t, 337t, 387t
Oxygenated groups, 8, 12, 13, 16, 377
14-Oxygenated substituents
 chemotaxonomy, 377
Oxygenation at C-6 and C-15, aconitine-subtypes (AIC), 10f, 106–128t
Oxygenation at C-6/nonoxygenation at C-15, aconitine-subtypes (AIB), 10f, 55–106t
- Paciline (BIC-41), 197t, 332t
Pacinine (BIC-33), 194–195t, 331t
Paclitaxel (Taxol®), 491
8-*O*-Palmitoylaconitine (lipoaconitine), 134–135t, 341t
8-*O*-Palmitoyl-14-*O*-anisoylbikhaconine, 341t
8-*O*-Palmitoyl-3-deoxyaconitine (lipo-3-deoxyaconitine), 341t
8-*O*-Palmitoylforesaconitine (lipoforesaconitine), 341t
8-*O*-Palmitoylhyapaconitine (lipohyapaconitine), 341t
8-*O*-Palmitoylindaconitine (lipindaconitine), 341t
8-*O*-Palmitoylmesaconitine (lipomesaconitine), 341t
8-*O*-Palmitoylpseudaconitine (lipopseudaconitine), 342t
8-*O*-Palmitoylyunaconitine (lipoyunaconitine), 342t
- Patentine (AIB-71), 81t, 335t
Penduline (AIC-7), 109–110t, 337t
Pengshenine A (AII-10), 137–138t, 330t
Pengshenine B (nagadine), 138–139t, 329t, 386t
Pentagydyne, 458t
Pentagydyne (BII-3), 235t, 329t, 389t
 α -fragmentation, 447f
Pentagylane (AIB-79), 84–85t, 334t
Pentagynine (AII-5), 136t, 329t
Peregrine (AIB-41), 72–73t, 332t, 539t
Peregrine alcohol (AIB-16), 63t, 330t, 475t, 539t
Peregrinine (AIII-6), 139–140t, 330t
Pergilone (BIB-24), 185t, 333t
- Pharmacology, 514–548
 analgesic effects, 515–516
 antiarrhythmic effects, 516–518
 anti-inflammatory effects, 514
 bioactivity, 519–548
 toxicity, 518–519
 toxicity–bioactivity relationships, 519
Pictumine (AIB-48), 74t, 333t
Piepunensine A (AIV-1), 142t, 329t
Pinacol rearrangements, 7, 374, 374f
Plant species, natural occurrences, 266–328
Poisoning
 antidotes, 516
 see also Toxicity
Polyschistine A (AIC-24 / szechenyine), 116t, 339t
Polyschistine B (AIC-42), 125–126t, 338t
Polyschistine C, 336t
Polyschistine D (AIC-22), 116t, 338t
Potanidine A (BId-56), 230–231t, 341t
Potanidine B (BId-21), 214–215t, 340t
Potanine (BIB-12), 181t, 331t
Potanisine A (BIV-3), 245t, 332t, 391t
Potanisine B (BIV-11), 248t, 339t
Potanisine C (BIV-4), 246t, 333t
Potanisine D (BIV-13), 249t, 337t
Potanisine E (BIV-12), 248t, 340t
Potanisine F (BId-42), 225t, 340t
Potanisine G (BId-46), 227t, 340t
Prins cyclizations, lycoctonine biosynthesis, 363f, 364
Processed aconite, 302t
Progress in compounds described, 4t
Protoaconines, lycoctonine biosynthesis, 368f, 369–370
Proton transfer, neoline fragmentation, 453f
Pseudaconine
 O-demethylations, 466
 glycol alcohol oxidation, 477, 479f
 methoxyl group eliminations, 465, 466f
 selective mesylation, 502
 α -Pseudaconitine (AIB-126), 103–104t, 340t
Pseudaconitine (AIB-126), 103–104t, 340t
Puberaconitidine (BId-47), 227t, 340t
Puberaconitine (*N*-(succinyl)
 anthranoyllycoctonine), 213–214t, 539t
Puberanine, 336t
Pubescenine (BIB-16), 183t, 333t, 540t
Pulchiline B (AIB-29), 68–69t, 331t
Pylzowine (BIB-2), 178t, 330t
Pyroaconitine, 522t
Pyrochasmaconitine (CI-3), 250t, 335t, 524t

- Pyrochasmanine (CI-2), 250t, 330t, 391t
 Pyrocrassicauline A (CI-4), 251t, 335t, 526t
 Pyrodelphinine, t458, 459f, 529t
 Pyrojesaconitine (CII-6), 253t, 337t
 Pyromesaconitine (CII-4), 253t
 Pyro-type alkaloids (C), 5–6, 11f, 14–15, 250–254t
 chemical shifts, 396t, 435t
 code numbers, 343–362
 double bond-subtypes, 250–252t
 α -fragmentation, 443
 H-8/CO-15-subtypes, 252–254t
 X-ray crystallography, 458t
- Quaternary carbons, 394–396t
- Racemuloline A (BIa-8), 147–148t, 330t
 Racemuloline B (AIa-29), 31–32t, 329t
 Ranaconitine, 540t, 547t
Ranunculaceae, diterpenoid occurrences, 266–302t
 Raveyine (AIa-13 / 8-O-methylcolumbianine), 26–27t, 329t, 524t
 Rearranged product of lycoctonine, t458, 459f
 Rearranged-type alkaloids (F), 5–6, 11, 263–264t, 458t
 biosynthesis, 372, 374, 374f
 chemical shifts, 396t, 437t
 code numbers, 343–362
 fragmentation ions, 444, 445f
 ring structures, 455
 Rearrangements, 484–489
 ring A, 484–485, 487f
 semipinacol-type, 485–488
 Wagner-Meerwein-type, 488–489
 Regioselective O-demethylations, 466–468
 Regioselective eliminations, hydroxyl groups, 464–465
 Ring A, 456–462
 conformation, 456–462
 fragmentation, 439, 440f
 rearrangements, 484–485, 487f
 sogorine-type fragmentation, 447f, 448
 taxoid synthesis, 494–498
 X-ray crystallography, 456–462
 Ring B, 484, 498–500
 Ring C, 500–507, 508f, 509f
 Ring D, 462–463, 515–516
- Ring structures
 conformation, 455–456
 envelope form, 456
 Royaline *see* Lycoctonine
 Royleinine (AIb-18), 63t, 330t
- Sachaconitine (vilmorrianine D), 28–29t, 329t
 Saponification, esters, 517
 Scaconine (AIa-24), 29–30t, 330t
 Scaconitine (AIa-93), 51t, 335t
 Secojesaconitine (E-11), 262t, 337t, 458t
 Secokaraconitine (E-12), 262t, 335t, 458t
 biosynthesis, 372, 373f
 ring A conformation, 462
 7,17-*Seco*-type alkaloids (E), 15–16, 259–262t
 biosynthesis, 372–374, 372f, 373f
 chemical shifts, 396t, 436–437t
 code numbers, 343–362
 crystallography, 458t
 Secoyunaconitine (E-8), 261t, 336t, 392t
 Selective anthranoylations, 479, 481f
 Selective hydrolysis, acetoxyl groups, 481–482
 Selective mesylations, pseudaconine, 502
 Semipinacol rearrangements, 485–488
 Semisynthesis, lycaconitine / methyllycaconitine, 490–491
 Senbusine A (AIb-4 / 6-O-demethylneoline / bataconine), 56–57t, 330t
 Senbusine B (AIa-85), 49t, 330t
 Senbusine C (15 α -hydroxynoline), 106–107t, 331t, 457t
 Sepaconitine, 540–541t, 547t
 Septedine, 541t, 547t
 Septentriodine (BIId-50 / cashmiradelphine), 228–229t, 340t
 Septephine, 541t, 547t
 Septerine (BIId-18), 213t, 336t
 Septonine (F-3), 263t, 337t
 fragmentation ions, 444, 445f
 Septontrionine (F-4), 263t, 331t
 fragmentation ions, 444, 445f
 Shawurensine (BIId-19), 214–215t, 340t
 Shimoburo base II *see* 14-Dehydrodelcosine
 Sinomontanine C, 337t
 Sinomontanine I (BIId-26), 217t, 338t
 Sinomontanitine A (AIa-100), 54t, 337t
 Sinomontanitine B (AIa-101), 54t, 338t
 Sinomontanitine C (AIa-99), 53t
 Sinonapellodine A (AIb-95), 91t, 335t
 Sinonapelloinine A (AIa-25), 30–31t, 335t

- Sinonapelloinine B (A1a-69), 43–44t, 336t
Siwanine A (B1c-63), 204t, 333t
Siwanine B (B1c-62), 204t, 333t
Siwanine C (B1c-65), 205t, 332t
Siwanine D (B1c-61), 204t, 332t, 458t
Siwanine E (B1c-57), 202–203t, 334t
Siwanine F (B1c-58), 203t, 333t
Skeleton structure, 5–7, 394, 395–396t
Sodelphinine (A1c-6), 108t
Soft ionization mass spectrometry, 450–454
Sogorine-type fragmentation, 447f, 448
Solvents, di-ester compound stability, 483–484
Soulidine (B1c-29), 193–194t, 333t
Souline A (A1b-32), 69–70t, 332t
Souline B (D-9), 257t, 331t, 391t
Souline C (B1c-28), 193–194t, 333t
Souline D (giralidine I) (A1a-2), 18t, 329t
Souline F (B1c-27), 193t, 333t
Spectral properties, 380–464
Spicatine A (14-*O*-benzoyl-8-*O*-ethylaconine), 117t, 337t
Spicatine B (A1c-5 / 10-dehydroxyflavaconitine), 108t, 336t
Stability, di-ester containing compounds, 483–484
Staphisadrine (A1b-55), 77t, 334t
Staphisadrinine (A1b-2), 55t, 330t
8-*O*-Stearoylaconitine (lipoaconine), 342t
8-*O*-Stearoyl-14-*O*-anisoylbikhaconine (lipo-14-*O*-anisoylbikhaconine), 342t
8-*O*-Stearoylbikhaconitine (lipobikhaconitine), 342t
8-*O*-Stearoyl-3-deoxyaconitine (lipo-3-deoxyaconitine), 342t
8-*O*-Stearoylhypaconitine (lipohypaconitine), 341t
8-*O*-Stearoylindaconitine (lipindaconitine), 342t
8-*O*-Stearoylmesaconitine (lipomesaconitine), 342t
8-*O*-Stearoylpseudaconitine (lipopseudaconitine), 342t
8-*O*-Stearoylyunaconitine (lipoyunaconitine), 342t
8-*O*-Steraoylforesaconitine (lipoforesaconitine), 342t
Steric effects, 12, 400, 409–410t
Structural modification, eliminations, 464–466
Structure determination, 381–410, 449–463
aconitines, 451–453
carbon-13 chemical shifts, 415–418t
double bonds, 399t
lipo-alkaloids, 451–453
lycoctonines, 454
moieties, 394, 397–398t
quaternary carbons, 394, 395–396t
ring A, 456–462
ring D, 462–463
steric effects, 400–410
Subcumine (A1b-31), 69–70t, 332t, 457t
Subcusine (A1b-8), 57–58t, 330t
Substituent groups, 7–16
aconitine-type alkaloids, 401–406t
effects, 516–518
carbon-13 chemical shifts, 400, 401–408t
chemical shifts, 382t, 415–418t
lycoctonine-type alkaloids, 407–408t
7,8-methylenedioxy groups, 498
molecular ion/base peaks, 448
sugar groups, 498
Substitutions, amino replacement of hydroxyl at C-8, 411, 414t
N-(Succinyl) anthranoyllycoctonine (puberaconitine), 213–214t, 339t
Sugar group introduction, 498
Sungpanconitine (A1b-68), 80–81t, 338t
Surface anesthesia, 520
Swatinine (B1a-60), 172t, 333t
Swinanine A (B1c-60), 203t, 333t
Swinanine B (B1c-59), 203t, 333t
Synthesis
lipo-alkaloids, 482
7,8-methylenedioxy groups, 498
oxaziridines, 475, 476f
taxoids, 491–514
yunaconitine, 500
Szechenyine (polyschistine A), 116t

Takao base I *see* Delcosine
Takaonine (B1a-71), 175t, 331t
Takaosamine (B1a-11), 148–149t, 331t, 541t
Talassicumine A (A1a-94), 52t, 336t
Talassicumine B (C1-7), 251–252t, 334t
Talassicumine C (A1a-86), 49t, 333t
Talatissamine-8-acetyl-14-*p*-methoxybenzoate (A1a-60), 41t, 336t, 541t
Talatissamine (A1a-11 / talatizamine), 23–26t, 330t, 468f, 541–542t, 547–548t
biosynthesis, 370, 371f
imination reactions, 472, 473t
Talatissamine-14-*p*-methoxybenzoate (A1a-59), 41t, 335t

- Talatizamine *see* Talatisamine
 Talatizidine (AIa-10), 23–25t, 329t, 542t
 Talitine A (BIc-46), 199t, 333t
 Talitine B (BIc-43), 198t, 332t
 Talitine C (BIc-45), 198t, 334t
 Tangirine (D-10), 258t, 341t, 391–392t
 Tatsidine (BIc-3), 185–186t, 330t, 542t
 Tatsienine V (BIc-4), 186–187t, 332t
 Tatiensine (BIc-30), 193–194t, 333t, 388t
 Tatsinine, 458t
 Tatsinine (BIa-9), 147–148t, 330t
 Taurenine (AIc-1 / 8-*O*-acetyl-15 α -hydroxyneoline), 106–107t, 333t
 Taxoids, 491–514
 deltaline conversion, 491, 493f, 494f, 507–514
 numbering, 492t
 ring A modifications, 494–498
 ring B modifications, 498–500
 ring C modifications, 500–507, 508f, 509f
 yunaconitine conversion, 491, 492f, 494–507
 Taxol[®] *see* Paclitaxel
 Taxotere[®] *see* Docetaxel
 Terdeline (BIc-68), 205–206t, 333t
 Tiantaishanmine (BIII-7), 242t, 331t
 Tiantaishannine (BIc-14), 189t, 332t
 Tongolenine C (BIII-1), 240t, 330t
 Tongolenine D (BIV-2), 245t, 330t, 391t
 Tongoline (isodelpheline), 196–197t, 331t
 Toroko base II *see* Chasmanine
 Toxicity, 518–519
 antidotes, 516
 bioactivity relationships, 519
 individual alkaloids, 521–548
 Transconitine A (AIa-58), 41t, 335t, 384t
 Transconitine B (AIb-117), 100–101t, 339t
 Transconitine C (AIII-4), 139–140t, 339t
 Transconitine D (AII-9), 137t, 335t, 386t
 Transconitine E (AIb-116), 100–101t, 338t
 3,13,14-Triacetyl-16-epipyroaconine, 458t, 459f
 3,13,15-*O*-Triacetylaconitine, 523t
 Trichocarpine A (D-11), 258t, 340t
 Trichocarpine B (D-12), 258t, 339t
 Tricornine (BIa-32), 161t, 333t, 387t
 Trifoliolasine A (BIId-6), 207–208t, 338t
 Trifoliolasine B (BIId-59), 231–232t, 339t
 Trifoliolasine C (BIId-60), 231–232t, 341t
 Tuberacconitine (AIc-35), 123–124t, 338t
 α -fragmentation, 442f
 Tuberanine (AIc-39 / 3-acetylmesaconitine), 124–125t, 339t
 α -fragmentation, 442f
 Tubermesaconitine (AIc-34), 123–124t, 337t
 α -fragmentation, 442f
 Tuguaconitine, 542–543t
 Turkosine (BIa-53), 170t, 332t
 Tursoline (BIa-55 / 10-hydroxydelsoline), 171t, 333t

 Umbrosine (BIa-5), 146t, 330t
 α,β -Unsaturated ketones, 16, 465
 Uraline (grandiflorine), 218t
 Uraphine (BIc-12), 188t, 332t

 Vaginadine (BIa-76), 177t, 331t
 Vaginaline (BIa-73), 176t, 331t
 Vaginatine (BIa-27), 156–157t, 331t
 Veatchines, biosynthesis, 368–369
 Venudelphine, 543t
 Venulol, 543t
 Venuluson, 543t
 14-*O*-Veratroylbikhaconine (AIb-123), 102t, 337t
 Veratroyl groups, chemical shifts, 383t, 418t
 6-*O*-Veratroylheteratisine, 533t, 546t
 14-*O*-Veratroylneoline (AIb-130), 105–106t, 336t
 Veratroypseudaconine (AIb-125), 103–104t, 338t
 Vilmoraconitine (F-5), 263t, 329t, 392t, 458t
 Vilmorisine (E-2), 15–16, 259t, 331t
 Vilmorine (E-9), 261t, 330t, 392t
 biosynthesis, 372, 373f
 Vilmorrianine A (AIb-101), 93–94t, 338t
 Vilmorrianine B *see* Karakoline
 Vilmorrianine C (foresaconitine), 91–92t, 337t
 Vilmorrianine D (sachaconitine), 28–29t
 Virescenine (BIa-4), 146–147t, 330t, 543
 fragmentation, 453
 Voltage-dependant sodium channels, 515–516
 Vulparine (BIId-4), 207–208t, 339t

 Wagner–Meerwein rearrangements, 362–368, 488–489
 aconitine biosynthesis, 362–364, 363f, 364f

- C_{20}/C_{19} alkaloid biogenesis, 366f, 367f, 368f
imine formation, 472
Winkleriline (B1c-2), 185–186t, 330t
- X-ray crystallography, 454–463
ring A, 456–462
- Yesoensine (B11-14), 238t, 331t
Yunaconitine (A1b-111 / guayewuanine B / isoaconitine), 97–99t, 339t, 543t
- N*-deethylation reactions, 470, 471f
methoxyl group elimination reactions, 465, 466f
synthesis, 500
taxoid synthesis, 491, 492f, 494–507
Yunnadelphinine (B1c-31), 194–195t, 330t, 458t
- Zaliline (B1V-9), 247t, 339t, 548t
Zeravschanine (heteratisine), 256t, 329t, 532–533t, 546t